COMPOSITIONS AND METHODS FOR SCREENING, MONITORING AND TREATING GASTROINTESTINAL DISEASES

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims a benefit of priority to US Patent Application

62/321,294, filed April 12, 2016, the entire disclosure of which is incorporated herein by reference.

TECHNICAL FIELD

This invention relates to compositions and methods for screening, diagnosing, monitoring and treating gastrointestinal (GI) diseases, including colorectal cancer, gastric cancer, liver cancer, and pancreatic cancer.

BACKGROUND OF THE INVENTION

Gastrointestinal (GI) diseases are complex chronic human disorders. GI diseases include colorectal cancer, gastric cancer, liver cancer, and pancreatic cancer. GI cancers account for a large percentage of cancer mortalities.

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women in the United States. Diet, environmental, genetic and inflammation factors contribute in the CRC etiology. Colorectal cancer usually develops over a period of 10 to 20 years. A significant progress has been made in the past decade in reducing the CRC incidence and death rates in the United States, largely due to prevention and early detection of colorectal cancer.

About 25,000 new stomach (gastric) cancer cases are reported in the United States annually. Before a stomach cancer develops, pre-cancerous changes often occur in the inner lining, mucosa, of the stomach. These early changes rarely cause symptoms and therefore often go undetected. The overall 5-year survival rate for patients with stomach cancer is 29% as most patients with stomach cancer are diagnosed after the cancer has already spread to other parts of the body. If stomach cancer is diagnosed and treated before it has spread outside the stomach, the 5-year survival rate is 65%. This data supports a high unmet need for developing a molecular test for detecting stomach cancer at early stages while the patient has not developed symptoms and the cancer has not spread outside the stomach.

Liver cancer is the 10th most common cancer and the 5th most common cause of cancer death among men. It is also the 8th most common cause of cancer death among women. The overall 5-year survival rate for patients with liver cancer is 18%. For 43% of people who are diagnosed at an early stage, the 5-year survival rate is 31%.

Pancreatic cancer (PC) is a lethal malignancy with a very high mortality rate. Pancreatic cancer is a group of heterogeneous diseases and includes cancer of the endocrine (islet cell carcinoma, neuroendocrine carcinoma and carcinoma of carcinoid tumors) and exocrine (pancreatic ductal adenocarcinoma and acinar) pancreas. Among these pathologies, pancreatic ductal adenocarcinoma accounts for approximately 90% of all cases. Notably, a significantly better treatment outcome has been reported in cases where a tumor was detected at an early stage.

Table A lists methods currently available for diagnosing pancreatic cancer.

Table A. Current Pancreatic Cancer Diagnostic Tests

As shown in Table A, detection of pancreatic cancer relies heavily on procedures, notably imaging. Advances in the imaging technology have allowed improved detection of small lesions. However, these advances have also led to increases in false- positive findings, necessitating invasive procedures to make a definitive diagnosis. Given the probability of false-positive findings associated with the CT screening, there is a substantial need for additional test methods to discriminate between benign vs malignant nodules. There are similar challenges in imaging-based screening for other GI malignancies and a high unmet need for highly sensitive and non-invasive diagnostic tests.

More than 2% of adults harbor a pancreatic cyst, a subset of which progresses to invasive lesions with lethal consequences. As the result of the increasing use of imaging technologies in standard medical practice, pancreatic cysts are being identified with an increasing frequency. Management of these cysts is concomitantly becoming a major clinical problem. Cystic lesions occur in more than 20% of patients examined at autopsy, in as many as 19.6% of patients evaluated by MRI, and in as many as 2.6% of patients evaluated by computed tomography. In the vast majority of cases, the cysts are identified as incidental findings in patients undergoing imaging for symptoms unrelated to pancreatic pathology. However, once a cyst is identified, it poses a challenging life-long management problem. Some cyst types are virtually always benign, some are low-grade malignant, and others are precursors to invasive pancreatic ductal adenocarcinomas. The distinction among cyst types is therefore critical for the effective management of patients with pancreatic cysts.

The potential for malignant transformation varies among pancreatic cystic neoplasms (PCN) subtypes. Imaging and a cyst fluid analysis are sometimes used to identify premalignant or malignant cases that should undergo operative resection. Therefore, there is a critical need to develop an efficient and noninvasive liquid biopsy test which can be used to distinguish a patient with a benign, non-premalignant disease from a patient with malignant pancreatic cysts.

A cancer is associated with major changes in biopathways, including upregulation of fucosyltransferases, sialyltransferases, mannosyl (a-l,6-)-glycoprotein β-1,6- N-acetyl-glucosaminyltransferase. Changes in the expression of glycosyltransferases result in altered glycan assembly, which occurs in the endoplasmic reticulum and Golgi. Accordingly, the glycoprotein products of tumor cells carry aberrant carbohydrate structures compared with their normal counterparts. Typical changes include increased levels of fucose and sialic acid, the addition of polylactosamine units and N-acetylglucosamine, and higher- ordered branching of N-linked glycans. O-linked glycans are also affected in cancer, typically carrying incomplete or prematurely truncated structures relative to those found on normal cells. After secretion or proteolytic cleavage, glycosylated molecules and/or their cleavage products can be released into the interstitial space, where they can enter the circulation. (Drake et al. 2010, Clin Chem, 56(2): 223-236) Ttumors produce glycoproteins that carry oligosaccharides with structures that are markedly different from the same protein produced by a normal cell. A single protein can have many glycosylation sites that greatly amplify the signals they generate compared with their protein backbones, thus tumor glycoproteins can serve as cancer biomarkers. The glycosylation machinery appears to be particularly sensitive to malignant transformation; as a result, the saccharide structures that are added to normal cellular proteins change, resulting in neoglycoforms that can be released from the cell through conventional secretory pathways, or as the result of enhanced proteinase activity. (Drake et al. 2010, Clin Chem, 56(2): 223-236)

Carbohydrates and their associated glycoproteins represent a rich, underexplored source of biomarkers. Glycoproteins with complex glycans are membrane bound or secreted. There is a substantial evidence that cancer cells exhibit altered glycans relative to normal cells. The potential of targeting glycoproteins to identify biomarkers was investigated by enriching N-linked glycopeptides from tissues, cells, and plasma and identifying corresponding peptide sequences and proteins by mass spectrometry. A significant overlap was observed between glycoproteins identified in tissues and cells and glycoproteins identified in plasma, leading to the conclusion that extracellular glycoproteins originating from tissues and cells are released into the blood at concentrations that are detectable by mass spectrometry. See US Patent Publication 2007/0099251.

It has been demonstrated that in pancreatic cancer glucose metabolism pathways and glycosylation levels are changing throughout disease progression, specifically on a background of hypoxia. Hypoxia promotes selective pressure on malignant cells that must develop adaptive metabolic responses to reach their energetic and biosynthetic demands. In a mouse model of pancreatic cancer, it was demonstrated that hypoxic areas from pancreatic ductal adenocarcinoma are mainly composed of epithelial cells harboring epithelial-mesenchymal transition features and expressing glycolytic markers, two characteristics associated with tumor aggressiveness. In this model, it has been also shown that hypoxia increases the "glycolytic" switch of pancreatic cancer cells from oxidative phosphorylation to lactate production and demonstrated that increased lactate efflux from hypoxic cancer cells favors the growth of normoxic cancer cells. (Guillaumond et al. 2013, PNAS, 1 10(10): 3919-3924).

Metabolized glucose and glutamine converge toward a common pathway, termed the hexosamine biosynthetic pathway, which allows O-linked N-acetylglucosamine modifications of proteins. Importantly, it was reported that hypoxia increases transcription of hexosamine biosynthetic pathway genes as well as levels of O-glycosylated proteins and that O-linked N-acetylglucosaminylation of proteins is a process required for hypoxic pancreatic cancer cell survival. Hypoxia-driven metabolic adaptive processes, such as high glycolytic rate and the hexosamine biosynthetic pathway activation, favor hypoxic and normoxic cancer cell survival and correlate with pancreatic cancer aggressiveness. (Guillaumond et al. 2013, PNAS, Mr 5; 110(10): 3919-3924).

In other studies, it was demonstrated that mucins, specifically, MUC1 and MUC4, are differentially glycosylated as the disease progressed from the early stage to metastatic disease. De novo expression of several mucins correlated with increased metastasis, indicating a potentially more invasive tumor phenotype. (Remmers et al. 2013, Clin Cancer Res. Apr 15: 19(8)).

There remains the need for an accurate and non-invasive test that can be used to detect and monitor a GI cancer.

SUMMARY

Provided is a method for screening, monitoring and/or treating a gastrointestinal (GI) cancer patient, wherein the GI cancer is selected from the group consisting of colorectal cancer, gastric cancer, liver cancer, and pancreatic cancer. A sample from the patient is obtained and glycosylated proteins are isolated from the sample. The isolated glycoproteins are then analyzed for the presence of any of biomarkers from Tables 1A, 2A, 3A, 4A, 5A, 6A, 7A, and any combination thereof. The presence of at least some of the biomarkes in the sample being indicative a GI cancer. The isolated glycosylated proteins can be also grouped into a profile of pathways, and matched with at least one profile selected from the group of profiles of Tables 1, 2, 3, 4, 5, 6, 7, 8, and any combination thereof. At least a partial match with at least one profile from Tables 1, 2, 3, 4, 5, 6, 7, 8 being indicative of a GI cancer.

The sample can be selected from the group consisting of a human tissue biopsy or biosample including pancreas biopsy sample, gastrointestinal sample, blood sample, plasma sample, serum sample, circulating tumor cells sample, tear sample, saliva sample, sperm sample, urine sample, fecal sample and hair sample. Blood or plasma samples are particularly preferred.

The sample can be analyzed using one or more techniques selected from the group consisting of chromatography, gas chromatography, liquid chromatography, mass spectrometry, ELISA, antibody linkage, immunoassay, biochip assay, microarray, nanoassay, spectroscopy, a multiplex molecular assay or techniques which utilize a fluorescent, enzyme, radioactive, metallic, biotin, chemiluminescent, bioluminescent molecule assay. The sample can be analyzed using a combination of a detection techniques of nucleic acids and proteins or peptides.

In the further embodiments of the method, any of biomarkers of Tables 1A, 1, 2A, 2, 3A, 3, 4A, 4, 5A, 5, 6A, 6, 7A and 7 are immobilized on a solid support.

The method can be conducted by reacting the patient's sample with at least one anybody or protein chemistry based reagent specific to at least one biomarker and/or glycobiomarker of Tables 1A, 1, 2A, 2, 3A, 3, 4A, 4, 5A, 6A, 6, 7A or 7. In further embodiments, the method can be conducted by reacting the patient's sample with a synthetic compound or probe which react with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 1A, 1, 2A, 2, 3A, 3, 4A, 4, 5A, 6A, 6, 7A or 7.

Further embodiments in provide a panel comprising a profile of biomarkers selected from the group consisting of Tables 1A, 1, 2A, 2, 3 A, 3, 4A, 4, 5 A, 6A, 6, 7A, 7 or8, and any combination thereof. Kits comprising the panels are provided as well.

Further embodiments provide a method for detecting or monitoring a disorder of the pancreas, the method comprising obtaining a sample from a patient and testing the sample for at least one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9. The disorder of the pancreas is selected from the group consisting of acute pancreatitis, chronic pancreatitis, hereditary pancreatitis, pancreatic neoplasm, and pancreatic cancer. The testing can be conducted by reacting the patient's sample with at least one anybody or protein chemistry based reagent specific to at least one biomarker and/or glycobiomarker of Tables 5A, 5, 6A, 6 and 9. The testing is conducted by reacting the patient's sample with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 5A, 5, 6A, 6 and 9. The testing can be also conducted by reacting the patient's sample with a synthetic compound or probe which react with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 5A, 5, 6A, 6 and 9.

Further embodiments provide a method for treating a disorder of the pancreas, the method comprising obtaining a sample from a mammal in need of the treatment and testing the sample for at least one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9. BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the relationship between 33 proteins in the Adherens Junction Assembly (Nectin) pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 2 shows the relationship between 66 proteins in the Bradykinin Effects in Inflammation pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 3 shows the relationship between 38 proteins in the coagulation cascade pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 4 shows the relationship between 25 proteins in the complement activation pathway by lectin. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 5 shows the relationship between 45 proteins in the complement activation in macular degeneration pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 6 shows the relationship between 30 proteins in the complement alternative pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 7 shows the relationship between 29 proteins in the complement cascade activation by pentraxin pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 8 shows the relationship between 28 proteins in the complement classical pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 9 shows the relationship between 37 proteins in the focal junction assembly pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 10 shows the relationship between 36 proteins in the glycolysis pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 11 shows the relationship between 33 proteins in the histidine-rich glycoprotein (HRG) pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 12 shows the relationship between 44 proteins in the lipogenesis regulation pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R . Fig. 13 shows the relationship between 26 proteins in the microtubule cytoskeleton pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 14 shows the relationship between proteins in the Neutrophil Activation via Adherence on Endothelial Cells pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 15 shows the relationship between proteins in the Plasmin Effects in Inflammation pathway. This figure was generated with ELSEVIER PATHWAY STUDIO*

Fig. 16 shows the relationship between proteins in the Platelet Activation via Adhesion Molecules pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 17 shows the relationship between proteins in the Platelet Activation via GPCR Signaling pathway. This figure was generated with ELSEVIER PATHWAY STUDIO*

Fig. 18 shows the relationship between proteins in the Positive Acute Phase Proteins Synthesis pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 19 shows the relationship between proteins in the Protein Folding pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 20 shows the relationship between proteins in the Scavenger Receptors in Platelet Activation pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 21 shows the relationship between proteins in the Scavenger Receptors in Platelet Aggregation pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 22 shows the relationship between proteins in the TAM Receptors in Platelet Aggregation pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R .

Fig. 23 shows the relationship between proteins in the Vascular Endothelial Cell Activation by Blood Coagulation Factors pathway. This figure was generated with ELSEVIER PATHWAY STUDIO ^R . DETAILED DESCRIPTION

This invention provides compositions and methods for detection, screening, monitoring and treatment of gastrointestinal (GI) cancers, including colorectal cancer, gastric cancer, liver cancer, and pancreatic cancer.

Provided is a method by which a patient's protein expression profile is obtained by isolating glycosylated proteins from the patient's liquid biopsy sample. Suitable liquid biopsy samples include blood, plasma, serum or urine. The glycosylated proteins in the profile are grouped into pathways and analyzed for deviations from a profile of a healthy individual. A deviation in a number of the glycosylated proteins in at least one pathway is indicative of the patient's GI cancer. This analysis can be used for developing a treatment plan for a patient with a particular emphasis on using drugs suitable for targeting the affected pathways and/or proteins.

A patient's profile of glycosylated proteins can be also obtained to evaluate results of cancer treatment, including a surgery, chemotherapy, radiation and/or immunotherapy. In this embodiment of the method, a patient's profile of glycosylated proteins after the cancer treatment is comparted to the patient's profile of glycosylated proteins before the cancer treatment. A decrease in the number of abnormally glycosylated proteins means that the treatment is beneficial to the patient. No changes or an increase in the number of abnormally glycosylated proteins means that the treatment plan needs to be modified or cancelled.

A patient's profile of glycosylated proteins can be also obtained to monitor the patient for an onset of a GI cancer. Many patients, including patients with a hereditary history of a GI cancer in a family, can benefit from this procedure which monitors the patient's profile of glycosylated proteins and pathways, and detects any changes in the profile over a period of time.

In one embodiment of the present methods, a patient's profile of glycosylated proteins is prepared by obtaining a blood, plasma, or serum sample from the patient. Glycosylated proteins are then isolated from the sample. Mass spectrometry of protein expression profile is performed to identify the glycosylated proteins in the sample. The patient's profile is then compared to a profile of a healthy individual in order to diagnose a GI cancer. This method can be used to diagnose a GI cancer. In alternative, a patient's profile of glycosylated proteins in a blood, plasma, or serum sample is monitored over a period of time by periodically repeating the analysis in order to detect an early onset of GI cancer or to determine if a particular cancer treatment is beneficial to the patient.

In alternative to the mass spectrometry analysis, a patient's profile of glycosylated proteins and affected pathways can be analyzed with a chip which comprises a set of biomarkers of a GI cancer. In further embodiments, the profiling of glycosylated proteins may comprise identifying affected pathways.

Table 1A discloses glycoproteins differentially expressed in plasma of colorectal cancer (CRC) female patients. These glycoproteins can be used for diagnosing, monitoring and treating a CRC patient by the present methods. In these methods, glycoproteins of Table 1A are used as a set of biomarkers indicative of CRC.

Table 1A. Glycoproteins differentially expressed in plasma of CRC female patients

Identified Proteins (739) Accession Number

14-3-3 protein sigma OS=Homo sapiens GN=SFN PE=1 SV=1 sp P31947 | 1433S_HUMAN

14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 sp P63104| 1433Z_HUMAN

78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 sp P11021 | GRP78_HUMAN

Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 sp P63261 |ACTG_HUMAN

Actin-related protein 2/3 complex subunit 2 OS=Homo sapiens GN=ARPC2 PE=1

SV=1 sp 015144 |ARPC2_HUMAN

Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1 SV=5 sp Q01518 | CAP1_HUMAN

AD P/ ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 P05141 | ADT2_HUMAN

P61204 |ARF3_HUMAN

ADP-ribosylation factor 3 OS=Homo sapiens GN=ARF3 PE=1 SV=2 (+1)

Alpha-l-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 P01009 |A1AT_HUMAN

Alpha-lB-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 P04217 |A1BG_HUMAN

Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 P02765 | FETUA_HUMAN

Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 P12814| ACTN1_HUMAN

Alpha-enolase OS=Homo sapiens GN=EN01 PE=1 SV=2 P06733 | ENOA_HUMAN

Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 P01019 |ANGT_HUMAN

Apolipoprotein A-l OS=Homo sapiens GN=APOAl PE=1 SV=1 P02647 | APOA1_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 P02649 |APOE_HUMAN

Apolipoprotein LI OS=Homo sapiens GN=APOLl PE=1 SV=5 014791 |APOLl_HUMAN

Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 P08519 | APOA_HUMAN

Arachidonate 12-lipoxygenase, 12S-type OS=Homo sapiens GN=ALOX12 PE=1 SV=4 P18054| LOX12_HUMAN

ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 P06576 |ATPB_HUMAN

Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 075882 | ATRN_HUMAN

Beta-pa rvin OS=Homo sapiens GN=PARVB PE=1 SV=1 Q9HBI1 | PARVB_HUMAN

Calpain-1 catalytic subunit OS=Homo sapiens GN=CAPN1 PE=1 SV=1 P07384 | CAN1_HUMAN

Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 P00915 | CAH1_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens GN=CPN1 PE=1 SV=1 P15169 | CBPN_HUMAN

Cathepsin G OS=Homo sapiens GN=CTSG PE=1 SV=2 P08311 | CATG_HUMAN

Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 00610 | CLHl_HUMAN Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp P10909 | CLUS_H UMAN

Coagulation factor IX OS=Homo sa piens GN=F9 PE=1 SV=2 sp P00740 | FA9_HUMAN

Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=4 sp P12259 | FA5_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2 sp P00742 | FA10_HUMAN

Coagulation factor XIII B chain OS=Homo sapiens GN=F13B PE=1 SV=3 sp P05160 | F13B_H UMAN

Complement Clq subcomponent subunit C OS=Homo sapiens GN=C1QC PE=1 SV=3 sp P02747 | Ci C_HUMAN

Complement Clr subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2 sp P00736 | C1R_HUMAN

Complement Cls subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 sp P09871 | C1S_HUMAN

Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 sp P06681 | CO2_H UMAN

Complement component C9 OS=Homo sapiens GI\I=C9 PE=1 SV=2 sp P02748 | CO9_HU AN

Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 sp P00751 | CFAB_HUMAN

Complement factor I OS=Homo sapiens GN=CFI PE=1 SV=2 sp P05156 | CFAI_HUMAN

Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 sp P08185 | CBG_H UMAN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 sp P02741 | CRP_HUMAN EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo sapiens

GN=EFEMP1 PE=1 SV=2 sp i2805 | FBLN3_HUMAN

Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 sp P14625 | ENPL_HUMAN Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1

SV=3 sp P27105 | STOM_HUMAN

Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 sp P15311 | EZRI_HUMAN

Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 sp Q86UX7 | URP2_HUMAN

Fetuin-B OS=Homo sapiens GN=FETUB PE=1 SV=2 sp Q9UGM51 FETUB_H UMAN

Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 sp P02675 | FIBB_HUMAN

Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 sp P02679 | FIBG_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 sp P02751 | FINC_HUMAN

Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 sp P21333 | FLNA_HUMAN

Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 sp P040751 ALDOA_H U M AN

Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 sp 08380 | LG3BP_HUMAN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 sp P06396 | GELS_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1

SV=3 sp P04406 | G3P_HUMAN

Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 sp P00738 | HPT_HUMAN

Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 sp P00739 | HPTR_HUMAN

Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 sp P11142 | HSP7C_HUMAN

Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 sp P08238 | HS90B_H UMAN

Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 sp P69905 | HBA_HUMAN Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1

SV=1 sp P61978 HNRPK_HUMAN

Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3 sp P19367 HXK1_HUMAN

Ig delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 sp P01880 IGHD_HUMAN lg gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 sp P01857 IGHG1_HUMAN

Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 sp P01861 IGHG4_HUMAN

Ig heavy chain V-l region HG3 OS=Homo sapiens PE=3 SV=1 sp P01743 HV102_HUMAN

Ig heavy chain V-l region WOL OS=Homo sapiens PE=1 SV=1 sp P01760 HV105_HUMAN

Ig heavy chain V-ll region ARH-77 OS=Homo sapiens PE=4 SV=1 sp P06331 HV209_HUMAN

Ig heavy chain V-ll region SESS OS=Homo sapiens PE=2 SV=1 sp P04438 HV208_HUMAN

Ig heavy chain V-lll region BUR OS=Homo sapiens PE=1 SV=1 sp P01773 HV312_HUMAN

Ig heavy chain V-lll region CAM OS=Homo sapiens PE=1 SV=1 sp P01768 HV307_HUMAN

Ig heavy chain V-lll region HIL OS=Homo sapiens PE=1 SV=1 sp P01771 HV310_HUMAN

Ig heavy chain V-lll region NIE OS=Homo sapiens PE=1 SV=1 sp P01770 HV309 HUMAN Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 sp P01834 | IGKC_HUMAN

Ig kappa chain V-l region Lay OS=Homo sapiens PE=1 SV=1 sp P01605 I KV113_HUMAN

Ig kappa chain V-l region Mev OS=Homo sapiens PE=1 SV=1 sp P01612 | KV120_HUMAN

Ig kappa chain V-ll region FR OS=Homo sapiens PE=1 SV=1 sp P01615 | KV202_HUMAN

Ig kappa chain V-ll region MIL OS=Homo sapiens PE=1 SV=1 sp P01616 | KV203_HUMAN

Ig kappa chain V-ll region RPMI 6410 OS=Homo sapiens PE=4 SV=1 sp P06310 | KV206_HUMAN

Ig kappa chain V-lll region CLL OS=Homo sapiens PE=4 SV=2 sp P04207 I KV308_HUMAN

Ig kappa chain V-lll region IARC/BL41 OS=Homo sapiens PE=4 SV=1 sp P06311 I KV311_HUMAN

Ig kappa chain V-lll region NG9 (Fragment) OS=Homo sapiens PE=2 SV=1 sp P01621 | KV303_HUMAN

Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 sp P04211 I LV001_HUMAN

Ig lambda chain V-l region HA OS=Homo sapiens PE=1 SV=1 sp P01700 | LV102_HUMAN

Ig lambda chain V-l region NEW OS=Homo sapiens PE=1 SV=1 sp P01701 | LV103_HUMAN

P01702 | LV104 HUMAN

Ig lambda chain V-l region NIG-64 OS=Homo sapiens PE=1 SV=1 (+ 1)

Ig lambda chain V-V region DEL OS=Homo sapiens PE=1 SV=1 sp P01719 | LV501_HUMAN Insulin-like growth factor-binding protein complex acid labile subunit OS=Homo

sapiens GN=IGFALS PE=1 SV=1 sp P35858 |ALS_HUMAN

Integrin alpha-lib OS=Homo sapiens GN=ITGA2B PE=1 SV=3 sp P08514 | ITA2B_HUMAN

Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 sp P05106 | ITB3_HUMAN

Integrin-linked protein kinase OS=Homo sapiens GN=ILK PE=1 SV=2 sp Q13418 | ILK_HUMAN Inter-alpha-trypsin inhibitor heavy chain HI OS=Homo sapiens GN=ITIH1 PE=1

SV=3 sp P19827 | ITIH1_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2 PE=1

SV=2 sp P48735 | IDHP_HUMAN

Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3 sp P29622 | KAIN_HUMAN

Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 sp P01042 | KNG1_HUMAN

Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 sp P02750| A2GL_HUMAN LIM and senescent cell antigen-like-containing domain protein 1 OS=Homo sapiens

GN=LIMS1 PE=1 SV=4 sp P48059 | LIMS1_HUMAN

Lipopolysaccharide-binding protein OS=Homo sapiens GN=LBP PE=1 SV=3 sp P18428| LBP_HUMAN

L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 sp P00338 | LDHA_HUMAN

L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 sp P07195 | LDHB_HUMAN

Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3 sp Q132011 MMRN1_HUMAN

Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 sp P60660 | MYL6_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 sp P35579 | MYH9_HUMAN

Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 sp P23284| PPIB_HUMAN

Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1

SV=2 sp 00325 | MPCP_HUMAN

Plasma protease CI inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 sp P05155 | IC1_HUMAN

Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1 SV=3 sp P05154 | IPSP_HUMAN

Platelet glycoprotein lb alpha chain OS=Homo sapiens GN=GP1BA PE=1 SV=2 sp P07359 | GP1BA_HUMAN

Platelet glycoprotein lb beta chain OS=Homo sapiens GN=GP1BB PE=1 SV=1 sp P13224 | GP1BB_HUMAN

Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3 sp P08567 | PLEK_HUMAN

Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 sp P07737 | PROF1_HUMAN

Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 sp P30101 | PDIA3_HUMAN

Proteoglycan 4 OS=Homo sapiens GN=PRG4 PE=1 SV=2 sp Q92954 | PRG4_HUMAN

Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP PE=1 SV=2 sp P00491 | PNPH_HUMAN Putative V-set and immunoglobulin domain-containing-like protein IGHV40R15-8

OS=Homo sapiens GN=IGHV40R15-8 PE=5 SV=2 sp A6NJ16 | IV4F8_HUMAN

Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 sp P14618 | KPYM_HUMAN

Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 sp P61026| RAB10_HUMAN Ras-related protein Rap-lb OS=Homo sapiens GN=RAP1B PE=1 SV=1 sp P61224 | RAP1B_HUMAN

Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2 sp Q9NQC31 RTN4_HUMAN

Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 OS=Homo sapiens

GN=ATP2A3 PE=1 SV=2 sp Q93084 |AT2A3_HUMAN

Serum amyloid P-component OS=Homo sapiens GN=APCS PE=1 SV=2 sp P02743 |SAMP_HUMAN

Solute carrier family 2, facilitated glucose transporter member 3 OS=Homo sapiens

GN=SLC2A3 PE=1 SV=1 sp P11169 | GTR3_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp 0.9 Y4901 TLN 1_H U M AN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 _HUMAN

Transgelin-2 OS=Homo sapiens GN PE=1 SV=3 _HUMAN

Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 |TTHY_HUMAN

Tubulin alpha-IB chain OS=Homo sapiens GN PE=1 SV=1 _HUMAN

Tubulin alpha chain OS=Homo sapiens GN PE=1 SV=1 _HUMAN

Tubulin beta-1 chain OS=Homo sapiens GN PE=1 SV=1 _HUMAN

Tubulin beta chain OS=Homo sapiens GN PE=1 SV=1 _HUMAN

Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 | VINC_HUMAN

Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 P02774 |VTDB_HUMAN

Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 P04004| VTNC_HUMAN

Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens

GN=VDAC3 PE=1 SV=1 Q9Y277 |VDAC3_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 P04275 | VWF_HUMAN

WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 075083 |WDR1_HUM AN

Table 1 provides a profile of abnormalities detected in pathways and glycosylated proteins in plasma of colorectal cancer female patients. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a CRC patient by the present methods. In these methods, the profile of Table 1 is used as a set of biomarkers indicative of CRC.

Table 1. A profile of abnormalities in pathways and glycosylated proteins in a CRC female patient.

Complement Activation in CFB, CFI, C2, CIR, CIS, C1QC, 1.11151E-8 4.97512E-2 Macular Degeneration C9, CRP, VTN, CLU

Focal Junction Assembly ACTN1, FLNA, FN1, TLNl, ILK, 1.66465E-8 4.87805E-2

VCL, CAPN1, VTN, LIMS1,

ITGB3

Platelet Activation via Adhesion GP1BA, FGB, FGG, ARPC2, 3.16888E-6 3.58423E-2 Molecules VCL, VWF, ITGA2B, ITGB3,

TLNl, GP1BB

Glycolysis HK1, GAPDH, ENOl, PKM, 1.60626E-5 3.40136E-2

ALDOA

TAM Receptors in Platelet FGB, FGG, VWF, ITGB3 9.25453E-5 2.87770E-2 Aggregation Scavenger Receptors in Platelet GP1BA, APOA1, APOE, 9.76831E-5 3.10881E-2 Activation ITGA2B, ITGB3, GP1BB

Complement Cascade Activation CFB, APCS, C2, CIS, C9, CRP 1.26998E-4 3.04569E-2 by Pentraxins

Complement Classical Pathway C2, CIR, CIS, C1QC, C9 1.29618E-4 3.01205E-2

Coagulation Cascade FGB, FGG, KNG1, F5, F9, F10 1.83636E-4 2.95567E-2

Scavenger Receptors in Platelet FGB, FGG, TLNl, ITGA2B, 1.96450E-4 2.92398E-2 Aggregation ITGB3

Table 2A discloses glycoproteins differentially expressed in plasma of colorectal cancer (CRC) male patients. These glycoproteins can be used for diagnosing, monitoring and treating a CRC patient by the present methods. In these methods, glycoproteins of Table 2A are used as a set of biomarkers indicative of CRC.

Table 2A. Glycoproteins differentially expressed in plasma of CRC male patients

Identified Proteins (739) Accession Number

14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 P63104 | 1433Z_HUMAN

Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 P63261 | ACTG_HUMAN

Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1 SV=5 01518 | CAPl_HUMAN

AD P/ ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 P05141 |ADT2_HUMAN

Alpha-lB-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 P04217 | A1BG_HUMAN

Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 P12814| ACTN1_HUMAN

Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 P04114 |APOB_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 P02649 |APOE_HUMAN

Apolipoprotein LI OS=Homo sapiens GN=APOLl PE=1 SV=5 0147911 APOLl_HUMAN

ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1

PE=1 SV=1 P25705 | ATPA_HUMAN

ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1

SV=3 P06576| ATPB_HUMAN

Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 P02749 |APOH_HUMAN

C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB PE=1 SV=1 P20851 | C4BPB_HUMAN

Cholesteryl ester transfer protein OS=Homo sapiens GN=CETP PE=1 SV=2 P11597 | CETP_HUMAN

Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Q00610 | CLH1_HUMAN

Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2 P00740 | FA9_HUMAN

Coagulation factor XI OS=Homo sapiens GN=F11 PE=1 SV=1 P03951 | FA11_HUMAN

Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3 P00748 | FA12_HUMAN

Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 P00488| F13A_HUMAN

Complement Clq subcomponent subunit A OS=Homo sapiens GN=C1QA PE=1

SV=2 P02745 | C1QA_HUMAN

Complement Clr subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2 P00736| C1R_HUMAN

Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 P00751 | CFAB_HUMAN

Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 P08185 | CBG_HUMAN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 P02741 | CRP_HUMAN

Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 P15924| DESP_HUMAN

EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo sapiens

GN=EFEMP1 PE=1 SV=2 i2805 | FBLN3_HUMAN

Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM P27105 | STOM_HUMAN PE=1 SV=3

Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 sp Q86UX7 | URP2_HUMAN

Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 sp P02671 FIBA_HUMAN

Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 sp P02675 FIBB_HUMAN

Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 sp P02679 FIBG_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 sp P02751 FINC_HUMAN

Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4 P23142 FBLN1_HUMAN

Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 P21333 FLNA_HUMAN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 P06396 GELS_HUMAN

Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 P22352 GPX3_HUMAN

Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH

PE=1 SV=3 P04406 G3P_HUMAN

Guanine nucleotide-binding protein G(k) subunit alpha OS=Homo sapiens

GN=GNAI3 PE=1 SV=3 P08754 GNAI3_HUMAN

Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 P11142 HSP7C_HUMAN

Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 P08238 HS90B_HUMAN

Hepatocyte growth factor-like protein OS=Homo sapiens GN=MST1 PE=1 SV=2 P26927 HGFL_HUMAN

Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 P62805 H4_HUMAN

Hyaluronan-binding protein 2 OS=Homo sapiens GN=HABP2 PE=1 SV=1 Q14520 | HABP2_HUMAN

Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 P01876 IGHA1_HUMAN

Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 P01877 IGHA2_HUMAN

Ig delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 P01880 IGHD_HUMAN

Ig heavy chain V-l region 5 (Fragment) OS=Homo sapiens GN=IGKVl-5 PE=4

SV=2 P01602 KV110_HUMAN

Ig heavy chain V-l region EU OS=Homo sapiens PE=1 SV=1 P01742 HV101_HUMAN

Ig heavy chain V-l region V35 OS=Homo sapiens PE=1 SV=1 P23083 HV103_HUMAN

Ig heavy chain V-ll region ARH-77 OS=Homo sapiens PE=4 SV=1 P06331 HV209_HUMAN

Ig heavy chain V-ll region NEWM OS=Homo sapiens PE=1 SV=1 P01825 HV207_HUMAN

Ig heavy chain V-ll region SESS OS=Homo sapiens PE=2 SV=1 P04438 HV208_HUMAN

Ig heavy chain V-ll region WAH OS=Homo sapiens PE=1 SV=1 P01824 HV206_HUMAN

Ig heavy chain V-lll region GA OS=Homo sapiens PE=1 SV=1 P01769 HV308_HUMAN

Ig heavy chain V-lll region KOL OS=Homo sapiens PE=1 SV=1 P01772 HV311_HUMAN

Ig heavy chain V-lll region NIE OS=Homo sapiens PE=1 SV=1 P01770 HV309_HUMAN

Ig heavy chain V-lll region TIL OS=Homo sapiens PE=1 SV=1 P01765 HV304_HUMAN

Ig heavy chain V-lll region WEA OS=Homo sapiens PE=1 SV=1 P01763 HV302_HUMAN

Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 P01834 IGKC_HUMAN

Ig kappa chain V-l region DEE OS=Homo sapiens PE=1 SV=1 P01597 KV105_HUMAN

Ig kappa chain V-l region Lay OS=Homo sapiens PE=1 SV=1 P01605 KV113_HUMAN

Ig kappa chain V-l region WEA OS=Homo sapiens PE=1 SV=1 P01610 KV118_HUMAN

Ig kappa chain V-ll region MIL OS=Homo sapiens PE=1 SV=1 P01616 KV203_HUMAN

Ig kappa chain V-ll region TEW OS=Homo sapiens PE=1 SV=1 P01617 KV204_HUMAN

Ig kappa chain V-lll region IARC/BL41 OS=Homo sapiens PE=4 SV=1 P06311 KV311_HUMAN

Ig kappa chain V-lll region VG (Fragment) OS=Homo sapiens PE=1 SV=1 P04433 KV309_HUMAN

Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 P04211 LV001_HUMAN

Ig lambda chain V-l region HA OS=Homo sapiens PE=1 SV=1 P01700 LV102_HUMAN

Ig lambda chain V-l region NEW OS=Homo sapiens PE=1 SV=1 P01701 LV103_HUMAN

Ig lambda chain V-l region NEWM OS=Homo sapiens PE=1 SV=1 P01703 LV105_HUMAN

Ig lambda chain V-l region WAH OS=Homo sapiens PE=1 SV=1 P04208 LV106_HUMAN

Ig lambda chain V-lll region LOI OS=Homo sapiens PE=1 SV=1 P80748 LV302_HUMAN Ig lambda chain V-lll region SH OS=Homo sapiens PE=1 SV=1 sp P01714| LV301_HUMAN

Ig lambda chain V-IV region Hil OS=Homo sapiens PE=1 SV=1 sp P01717 | LV403_HUMAN

IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 sp Q9Y6R71 FCGBP HUMAN

Insulin-like growth factor-binding protein complex acid labile subunit

OS=Homo sapiens GN=IGFALS PE=1 SV=1 sp P35858 |ALS_HUMAN

Integrin alpha-lib OS=Homo sapiens GN=ITGA2B PE=1 SV=3 sp P08514 | ITA2B_HUMAN

Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 sp P05106| ITB3_HUMAN Inter-alpha-trypsin inhibitor heavy chain HI OS=Homo sapiens GN=ITIH1 PE=1

SV=3 sp P19827 | ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1

SV=2 sp P19823 | ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH ₄ PE=1

SV=4 sp Q14624 | ITIH4_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2

PE=1 SV=2 sp P48735 | IDHP_HUMAN

Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 sp P14923 | PLAK_HUMAN

Keratinocyte proline-rich protein OS=Homo sapiens GN=KPRP PE=1 SV=1 sp 5T749 | KPRP_HUMAN

Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 sp P02750| A2GL_HUMAN

Lipopolysaccharide-binding protein OS=Homo sapiens GN=LBP PE=1 SV=3 sp P18428| LBP_HUMAN

Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3 sp Q132011 MMRN1_HUMAN

Myeloperoxidase OS=Homo sapiens GN=MPO PE=1 SV=1 sp P05164| PERM_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 sp P35579 | MYH9_HUMAN

Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 sp P23284 | PPIB_HUMAN Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1

SV=2 sp Q00325 | MPCP_HUMAN Phosphatidylinositol-glycan-specific phospholipase D OS=Homo sapiens

GN=GPLD1 PE=1 SV=3 sp P80108 | PHLD_HUMAN

Phospholipid transfer protein OS=Homo sapiens GN=PLTP PE=1 SV=1 sp P55058 | PLTP_HUMAN

Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3 sp P08567 | PLEK_HUMAN

Pregnancy zone protein OS=Homo sapiens GN=PZP PE=1 SV=4 sp P20742 | PZP_HUMAN

Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 sp P07737 | PROF1_HUMAN

Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 sp P30101 | PDIA3_HUMAN

Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 sp P05109|S10A8_HUMAN Protein Z-dependent protease inhibitor OS=Homo sapiens GN=SERPINA10 PE=1

SV=1 sp Q9UK55 | ZPI_HUMAN

Proteoglycan 4 OS=Homo sapiens GN=PRG4 PE=1 SV=2 sp Q92954 | PRG4_HUMAN

Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 sp P14618| KPYM_HUMAN

Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 sp P61026 | RAB10_HUMAN

Ras-related protein Rap-lb OS=Homo sapiens GN=RAP1B PE=1 SV=1 sp P61224 | RAP1B_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 OS=Homo sapiens

GN=ATP2A3 PE=1 SV=2 sp 93084 | AT2A3_HUMAN

Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PONl PE=1 SV=3 sp P27169 | P0N1_HUMAN

Sex hormone-binding globulin OS=Homo sapiens GN=SHBG PE=1 SV=2 sp P04278 |SHBG_HUMAN

Small proline-rich protein 2D OS=Homo sapiens GN=SPRR2D PE=2 SV=2 sp P22532 |SPR2D_HUMAN

Solute carrier family 2, facilitated glucose transporter member 3 OS=Homo

sapiens GN=SLC2A3 PE=1 SV=1 sp P11169 | GTR3_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp Q9Y4901 TLN 1_H U M AN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 sp P07996|TSP1_HUMAN

Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 sp P05543 |THBG_HUMAN

Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 sp P02766|TTHY_HUMAN

Tubulin alpha-IB chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 sp P68363 |TBA1B_HUMAN

Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 sp P07437 |TBB5_HUMAN

Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1 sp Q9H4B7 |TBB1_HUMAN Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 SV=1 sp I 0.13885 |TBB2A_HUMAN Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 sp | P18206| VINC_HUMAN

Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens

GN=VDAC3 PE=1 SV=1 sp I Q9Y2771 VDAC3 HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 sp | P04275 |VWF_HUMAN

WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 sp 10750831 WDR1_HUMAN

Table 2 provides a profile of abnormalities in pathways and glycosylated proteins in a colorectal cancer male patient. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a CRC patient by the present methods. In these methods, the profile of Table 2 is used as a set of biomarkers indicative of CRC.

Table 2. A profile of abnormalities in pathways and glycosylated proteins in a CRC male patient.

Scavenger Receptors ixt Platelet APOB, APOE, 2.10901E-3 2.27273E-2

Activation ITGA2B, ITGB3

Table 3A discloses glycoproteins differentially expressed in plasma of gastric cancer female patients. These glycoproteins can be used for diagnosing, monitoring and treating a gastric cancer patient by the present methods. In these methods, glycoproteins of Table 3 A are used as a set of biomarkers indicative of gastric cancer.

Table 3A Glycoproteins differentially expressed in plasma of gastric cancer female patients

14-3-3 protein sigma OS=Homo sapiens GN=SFN PE=1 SV=1 sp P31947 | 1433S_HUMAN

14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 sp P63104| 1433Z_HUMAN

78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 sp P11021 | GRP78_HUMAN

Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 sp P63261 |ACTG_HUMAN

Actin-related protein 2/3 complex subunit IB OS=Homo sapiens GN=ARPC1B PE=1

SV=3 sp 0151431 ARC1B_HUMAN Actin-related protein 2/3 complex subunit 4 OS=Homo sapiens GN=ARPC4 PE=1

SV=3 sp P59998 |ARPC4_HUMAN

Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1 SV=5 sp Q01518 | CAP1_HUMAN

AD P/ ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 sp P05141 | ADT2_HUMAN

ADP-ribosylation factor 3 OS=Homo sapiens GN=ARF3 PE=1 SV=2 sp P61204 |ARF3_HUMAN (+1)

Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 sp P08697 |A2AP_HUMAN

Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 sp P01023 |A2MG_HUMAN

Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 sp P12814| ACTN1_HUMAN

Alpha-enolase OS=Homo sapiens GN=EN01 PE=1 SV=2 sp P06733 | ENOA_HUMAN

Apolipoprotein A-l OS=Homo sapiens GN=APOAl PE=1 SV=1 sp P02647 | APOA1_HUMAN

Apolipoprotein LI OS=Homo sapiens GN=APOLl PE=1 SV=5 sp 0147911 AP0L1_HUMAN

Apolipoprotein M OS=Homo sapiens GN=APOM PE=1 SV=2 sp 0954451 APOM_HUMAN

Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 sp P08519 | APOA_HUMAN

ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1

SV=1 sp P25705 |ATPA_HUMAN

Beta-l,4-galactosyltransferase 1 OS=Homo sapiens GN=B4GALT1 PE=1 SV=5 sp P15291 | B4GT1_HUMAN

Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 sp P02749 |APOH_HUMAN

Beta-parvin OS=Homo sapiens GN=PARVB PE=1 SV=1 sp Q9HBI1 | PARVB_HUMAN

Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 sp P00915 | CAH1_HUMAN

Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 PE=1 SV=2 sp 96IY4 | CBPB2_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens GN=CPN1 PE=1 SV=1 sp P15169 | CBPN_HUMAN

Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1 SV=3 sp P22792 | CPN2_HUMAN

Cartilage acidic protein 1 OS=Homo sapiens GN=CRTAC1 PE=1 SV=2 sp Q9NQ79 | CRAC1_HUMAN

Cholinesterase OS=Homo sapiens GN=BCHE PE=1 SV=1 sp P06276 | CHLE_HUMAN

Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 sp 00610 | CLHl_HUMAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp P10909 | CLUS_HUMAN

Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2 sp P00740| FA9_HUMAN

Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=4 sp P12259 | FA5_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2 sp P00742 | FA10_HUMAN Coagulation factor XI OS=Homo sapiens GN=F11 PE=1 SV=1 sp | P03951 | FAll_HUMAN

Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3 sp I P007481 FA12_HUMAN

Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 sp | P00488 | F13A_HUMAN Complement Clq subcomponent subunit A OS=Homo sapiens GN=C1QA PE=1

SV=2 sp I P027451 ClCiA_HUMAN

Complement Clr subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2 sp | P00736 | ClR_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 sp | P01024| CO3_HUMAN

Complement component C8 beta chain OS=Homo sapiens GN=C8B PE=1 SV=3 sp | P07358 | CO8B_HUMAN

Complement factor H-related protein 1 OS=Homo sapiens GN=CFHR1 PE=1 SV=2 sp | Q03591 | FHRl_HUMAN

Complement factor H-related protein 5 OS=Homo sapiens GN=CFHR5 PE=1 SV=1 sp | 9BXR6 | FHR5_HUMAN

Complement factor I OS=Homo sapiens GN=CFI PE=1 SV=2 sp | P05156| CFAI_HUMAN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 sp | P02741 | CRP_HUMAN Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit

OS=Homo sapiens GN=DDOST PE=1 SV=4 sp I P39656| OST48_HUMAN

EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo sapiens

GN=EFEMP1 PE=1 SV=2 sp I Q128051 FBLN3_HUMAN

Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 sp | P14625 | ENPL_HUMAN

Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1

SV=3 sp I P27105 |STOM_HUMAN

Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 sp | P15311 | EZRI_HUMAN

F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=1 SV=4 sp I P477561 CAPZB_HUMAN Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 sp | 86UX7 | URP2_HUMAN Fetuin-B OS=Homo sapiens GN=FETUB PE=1 SV=2 sp I Q9UGM51 FETUB_HUMAN Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4 sp I P231421 FBLN1_HUMAN Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 sp | P21333 | FLNA_HUMAN

Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 sp I P040751 ALDOA_H U M AN

Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 sp I Q083801 LG3BP_H U M AN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 sp | P06396| GELS_HUMAN

Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 sp | P22352 | GPX3_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1

SV=3 sp | P04406 | G3P_HUMAN

Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 sp | P00738 | HPT_HUMAN

Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 sp I P007391 HPTR_HUMAN

Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 sp I P111421 HSP7C_HUMAN

Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 sp I P082381 HS90B_HUMAN

Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 sp | P69905 | HBA_HUMAN

Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 sp | P68871 | HBB_HUMAN

Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 sp I P055461 HEP2_HUMAN

Hepatocyte growth factor-like protein OS=Homo sapiens GN=MST1 PE=1 SV=2 sp | P26927 | HGFL_HUMAN

Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 sp | P04196 | HRG_HUMAN

Identified Proteins (739) Accession Number

Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 sp I P018611 IGHG4_HUMAN

Ig heavy chain V-l region EU OS=Homo sapiens PE=1 SV=1 sp I P017421 HV101_HUMAN

Ig heavy chain V-l region HG3 OS=Homo sapiens PE=3 SV=1 sp I P017431 HV102_HUMAN

Ig heavy chain V-l region WOL OS=Homo sapiens PE=1 SV=1 sp I P017601 HV105_HUMAN

Ig heavy chain V-ll region ARH-77 OS=Homo sapiens PE=4 SV=1 sp I P063311 HV209_HUMAN

Ig heavy chain V-ll region WAH OS=Homo sapiens PE=1 SV=1 sp I P018241 HV206_HUMAN

Ig heavy chain V-l 11 region 23 OS=Homo sapiens GN=IGHV3-23 PE=1 SV=2 sp I P017641 HV303_HUMAN

Ig heavy chain V-lll region BRO OS=Homo sapiens PE=1 SV=1 sp I P017661 HV305_HUMAN

Ig heavy chain V-lll region BUT OS=Homo sapiens PE=1 SV=1 sp I P017671 HV306_HUMAN Ig heavy chain V-lll region GAL OS=Homo sapiens PE=1 SV=1 sp P01781|HV320_HUMAN

Ig heavy chain V-lll region NIE OS=Homo sapiens PE=1 SV=1 sp P01770|HV309_HUMAN

Ig heavy chain V-lll region WEA OS=Homo sapiens PE=1 SV=1 sp P01763|HV302_HUMAN

Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 sp P01834|IGKC_HUMAN

Ig kappa chain V-l region CAR OS=Homo sapiens PE=1 SV=1 sp P01596|KV104_HUMAN

Ig kappa chain V-l region Mev OS=Homo sapiens PE=1 SV=1 sp P01612|KV120_HUMAN

Ig kappa chain V-ll region FR OS=Homo sapiens PE=1 SV=1 sp P01615|KV202_HUMAN

Ig kappa chain V-ll region RPMI 6 ₄ 10 OS=Homo sapiens PE=4SV=1 sp P06310|KV206_HUMAN

Ig kappa chain V-IV region STH (Fragment) OS=Homo sapiens PE=1 SV=1 sp P83593|KV405_HUMAN

Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 sp P04211|LV001_HUMAN

Ig lambda chain V-l region HA OS=Homo sapiens PE=1 SV=1 sp P01700|LV102_HUMAN

Ig lambda chain V-l region NEWM OS=Homo sapiens PE=1 SV=1 sp P01703|LV105_HUMAN

Ig lambda chain V-l region NIG-64 OS=Homo sapiens PE=1 SV=1 sp P01702|LV104_HUMAN (+1)

Ig lambda chain V-ll region TRO OS=Homo sapiens PE=1 SV=1 sp P01707|LV204_HUMAN

IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 sp Q9Y6R71 FCGBP HUMAN

Integrin alpha-lib OS=Homo sapiens GN=ITGA2B PE=1 SV=3 sp P08514|ITA2B_HUMAN

Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 sp P05106|ITB3_HUMAN

Integrin-linked protein kinase OS=Homo sapiens GN=ILK PE=1 SV=2 sp Q13418|ILK_HUMAN

Inter-alpha-trypsin inhibitor heavy chain HI OS=Homo sapiens GN=ITIH1 PE=1

SV=3 sp P19827|ITIH1_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens GN=ITIH3 PE=1

SV=2 sp Q06033|ITIH3_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1

SV=4 sp i4624|ITIH4_HUMAN

Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2 PE=1

SV=2 sp P48735|IDHP_HUMAN

Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 sp P14923|PLAK_HUMAN

Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 sp P35527|K1C9_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 sp P04264|K2C1_HUMAN

Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 sp P35908|K22E_HUMAN

Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 sp P01042|KNG1_HUMAN LIM and senescent cell antigen-like-containing domain protein 1 OS=Homo sapiens

GN=LIMS1PE=1SV=4 sp P48059|LIMS1_HUMAN

L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 sp P00338|LDHA_HUMAN

Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 sp P61626|LYSC_HUMAN

Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3 sp 0132011 MMRN1_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 sp P35579|MYH9_HUMAN

N-acetylmuramoyl-L-alanine amidase OS=Homo sapiens GN=PGLYRP2 PE=1 SV=1 sp 96PD5|PGRP2_HUMAN

Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 sp P23284|PPIB_HUMAN

Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 sp P32119|PRDX2_HUMAN

Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 sp P30041|PRDX6_HUMAN

Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC2SA3 PE=1

SV=2 sp Q00325|MPCP_HUMAN

Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 SV=4 sp P36955|PEDF_HUMAN

Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1 SV=3 sp P05154|IPSP_HUMAN

Plastin-2 OS=Homo sapiens GN=LCP1 PE=1 SV=6 sp P13796|PLSL_HUMAN

Platelet glycoprotein lb alpha chain OS=Homo sapiens GN=GP1BA PE=1SV=2 sp P07359|GP1BA_HUMAN

Platelet glycoprotein lb beta chain OS=Homo sapiens GN=GP1BB PE=1 SV=1 sp P13224|GP1BB_HUMAN

Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3 sp P08567|PLEK_HUMAN

Pregnancy zone protein OS=Homo sapiens GN=PZP PE=1 SV=4 sp P20742|PZP_HUMAN

Prenylcysteine oxidase 1 OS=Homo sapiens GN=PCYOXl PE=1 SV=3 sp 9UHG3|PCYOX_HUMAN Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 sp P07737 | PROF1_HUMAN

Protein broad-minded OS=Homo sapiens GN=TBC1D32 PE=2 SV=4 sp Q96NH3 | BROMI HUMAN

Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 sp P30101 | PDIA3_HUMAN

Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 sp P05109 | S10A8_HUMAN

Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 sp P06702 | S10A9_HUMAN

Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3 sp P12931 | SRC_HUMAN Putative V-set and immunoglobulin domain-containing-like protein IGHV40R15-8

OS=Homo sapiens GN=IGHV40R15-8 PE=5 SV=2 sp A6NJ16 | IV4F8_HUMAN

Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 sp P14618 | KPYM_HUMAN

Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 sp P61026| RAB10_HUMAN

Ras-related protein Rap-lb OS=Homo sapiens GN=RAP1B PE=1 SV=1 sp P61224 | RAP1B_HUMAN

Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1 SV=3 sp P02753 | RET4_HUMAN

Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 OS=Homo sapiens

GN=ATP2A3 PE=1 SV=2 sp Q93084 |AT2A3_HUMAN

Serum amyloid P-component OS=Homo sapiens GN=APCS PE=1 SV=2 sp P02743 | SAMP_HUMAN

Small proline-rich protein 2D OS=Homo sapiens GN=SPRR2D PE=2 SV=2 sp P22532 |SPR2D_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp Q9 Y4901 TLN 1_H U M AN Telomere length regulation protein TEL2 homolog OS=Homo sapiens GN=TEL02

PE=1 SV=2 sp Q9Y4R81 TEL02 H U M AN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 sp P07996 |TSP1_HUMAN

Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 sp P02766 |TTHY_HUMAN

Tubulin alpha-IB chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 sp P68363 |TBA1B_HUMAN

Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 SV=1 sp P68366 |TBA4A_HUMAN

Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 sp P07437 |TBB5_HUMAN

Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1 sp Q9H4B7 |TBB1_HUMAN

Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 SV=1 sp Q13885 |TBB2A_HUMAN

Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens GN=UBA52 PE=1 SV=2 sp P62987 | RL40_HUMAN

Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 sp P18206| VINC_HUMAN

Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens

GN=VDAC3 PE=1 SV=1 sp 9Y277 |VDAC3_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 sp P04275 |VWF_HUMAN

WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 sp 075083 |WDR1_HUMAN

Table 3 provides a profile of abnormalities in pathways and glycosylated proteins in a gastric cancer female patient. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a gastric cancer patient by the present methods. In these methods, the profile of Table 3 is used as a set of biomarkers indicative of gastric cancer.

Table 3. A profile of abnormalities in pathways and glycosylated proteins in a gastric cancer female patient.

Focal Junction Assembly SRC, ACTN1, FLNA, 5.15265E-6 3.57143E-2

TLN1, ILK, VCL, LIMS1,

ITGB3

Platelet Activation via Adhesion GP1BA, SRC, ARPC4, 6.77864E-6 3.37838E-2

Molecules ARPC1B, VCL, VWF,

ITGA2B, ITGB3, TLN1,

GP1BB

Coagulation Cascade KNG1, F5, F9, Fl l, F10, 3.29309E-5 3.19635E-2

F12, F13A1

Adherens Junction Asseniblv SRC, ARPC4, ARPC1B, 1.91850E-4 2.73224E-2 eciin) ACTN1, VCL

Protein Folding TUBB2A, TUBA4A, 3.15167E-4 2.70270E-2

TUBB, TUBA1B, TUBB1,

HSPA8, HSP90B1

GlvcoJvsis GAPDH, ENOl, PKM, 4.01213E-4 2.42424E-2

ALDOA

Neutrophil Activation via ARPC4, ARPC1B, ACTN1, 5.85006E-4 2.57511E-2 Adherence on Endothelial Ceils TLN1, VCL, ITGB3

Κ!. ^, ;ίΥί.·::;;€·!' Ree ni- ^j rs in Pu- i k j GP1BA, APOA1, ITGA2B, 1.29150E-3 2.36967E-2

Activation ITGB3, GP1BB

Microtubule Cvtoskeleton TUBB2A, TUBA4A, 1.29150E-3 2.36967E-2

TUBB, TUBA1B, TUBB1

Table 4A discloses glycoproteins differentially expressed in plasma of gastric cancer male patients. These glycoproteins can be used for diagnosing, monitoring and treating a gastric cancer patient by the present methods. In these methods, glycoproteins of Table 4A are used as a set of biomarkers indicative of gastric cancer.

Table 4A. Glycoproteins differentially expressed in plasma of gastric male patients

Identified Proteins (739) Accession Number

14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 sp P63104 | 1433Z_HUMAN

Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 sp P63261 |ACTG_HUMAN

Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1

SV=5 sp Q01518 | CAP1_HUMAN

AD P/ ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 sp P05141 |ADT2_HUMAN

Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 sp P43652 | AFAM_HUMAN

Alpha-lB-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 P04217 | A1BG_HUMAN

Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 P08697 | A2AP_HUMAN

Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 P01023 |A2MG_HUMAN

Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 P12814|ACTN1_HUMAN

Alpha-enolase OS=Homo sapiens GN=EN01 PE=1 SV=2 P06733 | ENOA_HUMAN

Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 P01019 |ANGT_HUMAN

Antithrombin-lll OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 P01008 |ANT3_HUMAN

Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 P04114 |APOB_HUMAN

Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 P05090 |APOD_HUMAN Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 sp P02649|APOE_HUMAN

Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 sp P08519|APOA_HUMAN ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1

PE=1SV=1 sp P25705|ATPA_HUMAN ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B

PE=1SV=3 sp P06576|ATPB_HUMAN

C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB PE=1 SV=1 sp P20851|C4BPB_HUMAN

Calpain-1 catalytic subunit OS=Homo sapiens GN=CAPN1 PE=1 SV=1 sp P07384|CAN1_HUMAN

Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 sp P00915|CAH1_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens GN=CPN1 PE=1 SV=1 sp P15169|CBPN_HUMAN

Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1 SV=3 sp P22792|CPN2_HUMAN

Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 sp P00450|CERU_HUMAN

Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 sp 00610|CLHl_HUMAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp P10909|CLUS_HUMAN

Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=4 sp P12259|FA5_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2 sp P00742|FA10_HUMAN

Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3 sp P00748|FA12_HUMAN

Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 sp P00488|F13A_HUMAN

Coagulation factor XIII B chain OS=Homo sapiens GN=F13B PE=1 SV=3 sp P05160|F13B_HUMAN Complement Clq subcomponent subunit A OS=Homo sapiens GN=C1QA

PE=1 SV=2 sp P02745|C1QA_HUMAN Complement Clq subcomponent subunit B OS=Homo sapiens GN=C1C;B

PE=1SV=3 sp P02746|Ci B_HUMAN

Complement Cls subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 sp P09871|C1S_HUMAN

Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 sp P06681|CO2_HUMAN

Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 sp P01024|CO3_HUMAN

Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 sp P0C0L4|CO4A_HUMAN

Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 sp P0C0L5|CO4B_HUMAN

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 sp P01031|CO5_HUMAN

Complement component C6 OS=Homo sapiens GN=C6 PE=1 SV=3 sp P13671|C06_HUMAN

Complement component C7 OS=Homo sapiens GN=C7 PE=1 SV=2 sp P10643|CO7_HUMAN

Complement component C8 alpha chain OS=Homo sapiens GN=C8A PE=1

SV=2 sp P07357|CO8A_HUMAN

Complement component C8 beta chain OS=Homo sapiens GN=C8B PE=1

SV=3 sp P07358|CO8B_HUMAN

Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 sp P08603|CFAH_HUMAN Complement factor H-related protein 1 OS=Homo sapiens GN=CFHR1 PE=1

SV=2 sp 03591|FHRl_HUMAN

Complement factor I OS=Homo sapiens GN=CFI PE=1 SV=2 sp P05156|CFAI_HUMAN

Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 sp P08185|CBG_HUMAN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 sp P02741|CRP_HUMAN

Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 sp P15924|DESP_HUMAN

Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 sp P14625|ENPL_HUMAN

Erythrocyte band 7 integral membrane protein OS=Homo sapiens

GN=STOM PE=1SV=3 sp P27105|STOM_HUMAN

Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 sp P15311|EZRI_HUMAN

Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 sp 86UX7|URP2_HUMAN

Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 sp P21333|FLNA_HUMAN

Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 sp P040751 ALDOA_H U M AN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 sp P06396|GELS_HUMAN

Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 sp P22352|GPX3_HUMAN

Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens sp P04406|G3P_HUMAN GN=GAPDH PE=1SV=3

Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1

SV=1 sp I P111421 HSP7C_HUMAN

Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1

SV=4 P08238|HS90B_HUMAN

Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 P68871|HBB_HUMAN

Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 P02790|HEMO_HUMAN

Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3 P19367|HXK1_HUMAN

Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 P62805|H4_HUMAN

Hyaluronan-binding protein 2 OS=Homo sapiens GN=HABP2 PE=1 SV=1 i4520|HABP2_HUMAN g heavy chain V-l region EU OS=Homo sapiens PE=1 SV=1 P01742|HV101_HUMAN g heavy chain V-l region HG3 OS=Homo sapiens PE=3 SV=1 P01743|HV102_HUMAN g heavy chain V-l region V35 OS=Homo sapiens PE=1 SV=1 P23083|HV103_HUMAN g heavy chain V-l region WOL OS=Homo sapiens PE=1 SV=1 P01760|HV105_HUMAN g heavy chain V-l 11 region 23 OS=Homo sapiens GN=IGHV3-23 PE=1 SV=2 P01764|HV303_HUMAN g heavy chain V-l 11 region BUT OS=Homo sapiens PE=1 SV=1 P01767|HV306_HUMAN g heavy chain V-l 11 region CAM OS=Homo sapiens PE=1 SV=1 P01768|HV307_HUMAN g heavy chain V-lll region GAL OS=Homo sapiens PE=1 SV=1 P01781|HV320_HUMAN g kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 P01834|IGKC_HUMAN g kappa chain V-l region DEE OS=Homo sapiens PE=1 SV=1 P01597|KV105_HUMAN g kappa chain V-l region Mev OS=Homo sapiens PE=1 SV=1 P01612|KV120_HUMAN g kappa chain V-l region WEA OS=Homo sapiens PE=1 SV=1 P01610|KV118_HUMAN g kappa chain V-ll region RPMI 6410 OS=Homo sapiens PE=4SV=1 P06310|KV206_HUMAN g kappa chain V-lll region HAH OS=Homo sapiens PE=2 SV=1 P18135|KV312_HUMAN g kappa chain V-lll region VG (Fragment) OS=Homo sapiens PE=1 SV=1 P04433|KV309_HUMAN g lambda chain V-l region VOR OS=Homo sapiens PE=1 SV=1 P01699|LV101_HUMAN g lambda chain V-lll region LOI OS=Homo sapiens PE=1 SV=1 P80748|LV302_HUMAN g lambda chain V-IV region Hil OS=Homo sapiens PE=1 SV=1 P01717|LV403_HUMAN gGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 Q9Y6R71 FCGBP HUMAN nsulin-like growth factor-binding protein complex acid labile subunit

OS=Homo sapiens GN=IGFALS PE=1 SV=1 P35858|ALS_HUMAN ntegrin alpha-lib OS=Homo sapiens GN=ITGA2B PE=1 SV=3 P08514|ITA2B_HUMAN ntegrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 P05106|ITB3_HUMAN nter-alpha-trypsin inhibitor heavy chain HI OS=Homo sapiens GN=ITIH1

PE=1SV=3 P19827|ITIH1_HUMAN nter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2

PE=1SV=2 P19823|ITIH2_HUMAN nter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens GN=ITIH3

PE=1 SV=2 06033|ITIH3_HUMAN nter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4

PE=1 SV=4 i4624|ITIH4_HUMAN socitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens

GN=IDH2 PE=1SV=2 P48735|IDHP_HUMAN

Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 P14923|PLAK_HUMAN

Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3 P29622|KAIN_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 P04264|K2C1_HUMAN Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1

SV=2 P35908|K22E_HUMAN

Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 Q8N1N4|K2C78_HUMAN Keratinocyte proline-rich protein OS=Homo sapiens GN=KPRP PE=1 SV=1 5T749|KPRP_HUMAN Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 P01042|KNG1_HUMAN Lipopolysaccharide-binding protein OS=Homo sapiens GN=LBP PE=1 SV=3 P18428|LBP_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 sp P00338 | LDHA_HUMAN

Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 sp P61626 | LYSC_HUMAN

Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3 sp 013201 MMRN1_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 sp P35579 | MYH9_HUMAN N-acetylmuramoyl-L-alanine amidase OS=Homo sapiens GN=PGLYRP2 PE=1

SV=1 sp 96PD5 | PGRP2_HUMAN

Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 sp P23284| PPIB_HUMAN

Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 sp P32119 | PRDX2_HUMAN

Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1

SV=4 sp P36955 | PEDF_HUMAN

Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1 sp P03952 | KLKB1_HUMAN

Plasma protease CI inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 sp P05155 | IC1_HUMAN

Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1

SV=3 sp P05154 | IPSP_HUMAN

Platelet glycoprotein lb alpha chain OS=Homo sapiens GN=GP1BA PE=1

SV=2 sp P07359 | GP1BA_HUMAN

Platelet glycoprotein lb beta chain OS=Homo sapiens GN=GP1BB PE=1 SV=1 sp P13224| GP1BB_HUMAN

Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3 sp P08567 | PLEK_HUMAN

Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 sp P07737 | PROF1_HUMAN

Protein AM BP OS=Homo sapiens GN=AMBP PE=1 SV=1 sp P02760 |AMBP_HUMAN

Protein broad-minded OS=Homo sapiens GN=TBC1D32 PE=2 SV=4 sp Q96NH3 | BROMI HUMAN

Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 sp P30101 | PDIA3_HUMAN

Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 sp P05109 |S10A8_HUMAN

Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 sp P00734|THRB_HUMAN

Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP PE=1 SV=2 sp P00491 | PNPH_HUMAN

Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 sp P14618| KPYM_HUMAN

Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 sp P61026| RAB10_HUMAN

Ras-related protein Rap-lb OS=Homo sapiens GN=RAP1B PE=1 SV=1 sp P61224| RAP1B_HUMAN

Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2 sp Q9NQC3 RTN4_HUMAN

Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1 SV=3 sp P02753 | RET4_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 OS=Homo sapiens

GN=ATP2A3 PE=1 SV=2 sp 93084 |AT2A3_HUMAN

Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PONl PE=1 SV=3 sp P27169 | P0N1_HUMAN

Skin-specific protein 32 OS=Homo sapiens GN=XP32 PE=1 SV=1 sp 5T750 |XP32_HUMAN

Small proline-rich protein 2D OS=Homo sapiens GN=SPRR2D PE=2 SV=2 sp P22532 | SPR2D_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp Q9Y490 TLN 1_H U M AN Telomere length regulation protein TEL2 homolog OS=Homo sapiens

GN=TEL02 PE=1 SV=2 sp Q9Y4R8 TE L02 H U M AN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 sp P07996 |TSP1_HUMAN

Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 sp P05543 |THBG_HUMAN

Tubulin alpha-IB chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 sp P68363 |TBA1B_HUMAN

Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 sp P07437 |TBB5_HUMAN

Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1 sp Q9H4B7 |TBB1_HUMAN

Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 SV=1 sp Q13885 |TBB2A_HUMAN

Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 sp P18206| VINC_HUMAN Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens

GN=VDAC3 PE=1 SV=1 sp 9Y277 |VDAC3_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 sp P04275 |VWF_HUMAN

WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 sp 075083 WDR1_HUMAN

Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 sp P25311 | ZA2G_HUMAN Table 4 provides a profile of abnormalities in pathways and glycosylated proteins in a gastric cancer male patient. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a gastric cancer patient by the present methods.

Table 4. A profile of abnormalities in pathways and glycosylated proteins in a gastric cancer male patient.

Table 5A discloses glycoproteins differentially expressed in plasma of pancreatic adenocarcinoma female patients. These glycoproteins can be used for diagnosing, monitoring and treating a pancreatic adenocarcinoma patient by the present methods. In these methods, glycoproteins of Table 5A are used as a set of biomarkers indicative of pancreatic adenocarcinoma cancer. Table 5A. Glycoproteins differentially expressed in plasma of pancreatic adenocarcinoma cancer (PADC) female patients

Identified Proteins Accession Number

Actin, cytoplasmic 1 OS=Homo sapiens G N=ACTB PE=1 SV=1 sp P60709 ACTB_HUMAN

Alpha-l-acid glycoprotein 1 OS=Homo sapiens G N=ORM l PE=1 SV=1 sp P02763 A1AG1_HUMAN

Alpha-l-antichymotrypsin OS=Homo sapiens GN=SERPI NA3 PE=1

SV=2 sp P01011 AACT_HUMAN

Alpha-l-antitrypsin OS=Homo sapiens G N=SERPINA1 PE=1 SV=3 sp P01009 A1AT_HU AN

Alpha-lB-glycoprotein OS=Homo sapiens G N=A1BG PE=1 SV=4 sp P04217 A1BG_HUMAN

Alpha-2-antiplasmin OS=Homo sapiens GN=SERPI NF2 PE=1 SV=3 sp P08697 A2AP_HUMAN

Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 sp P01019 ANGT_HUMAN

Apolipoprotein A-l OS=Homo sapiens GN=APOAl PE=1 SV=1 sp P02647 AP0A1_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 sp P02649 APOE_HUMAN

Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 sp P02749 APOH_HUMAN

C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1

SV=2 sp P04003 C4BPA_HUMAN

Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 PE=1 SV=2 sp Q96IY4 | CBPB2_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens GN=CPN1

PE=1 SV=1 sp P15169 CBPN_HU AN

Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1

SV=3 sp P22792 CPN2_HUMAN

CD5 antigen-like OS=Homo sapiens G N=CD5L PE=1 SV=1 sp 043866 | CD5L_HUMAN

Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 sp P00450 CERU_HUMAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp P10909 CLUS_HUMAN

Complement Cls subcomponent OS=Homo sapiens G N=C1S PE=1

SV=1 sp P09871 C1S_HUMAN

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 sp P01031 C05_HUMAN

Complement component C7 OS=Homo sapiens GN=C7 PE=1 SV=2 sp P10643 C07_HUMAN

Complement component C9 OS=Homo sapiens GN=C9 PE=1 SV=2 sp P02748 C09_HUMAN

Complement factor 1 OS=Homo sapiens GN=CFI PE=1 SV=2 sp P05156 CFAI_HU AN

Corticosteroid-binding globulin OS=Homo sapiens G N=SERPI NA6

PE=1 SV=1 sp P08185 CBG_HUMAN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 sp P02741 CRP_HUMAN

Desmoplakin OS=Homo sapiens G N=DSP PE=1 SV=3 sp P15924 DESP_HUMAN

EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo

sapiens GN=EFEM P1 PE=1 SV=2 sp Q12805 | FBLN3_HUMAN

Fibrinogen alpha chain OS=Homo sapiens G N=FGA PE=1 SV=2 sp P02671 FIBA_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 sp P02751 FINC_HUMAN

Fibulin-1 OS=Homo sapiens GN=FBLN 1 PE=1 SV=4 sp P23142 FBLN1_HUMAN

Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2 sp 075636 FCN3_HUMAN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 sp P06396 GELS_HU AN

Haptoglobin OS=Homo sapiens GN=H P PE=1 SV=1 sp P00738 HPT_HUMAN

Hemoglobin subunit alpha OS=Homo sapiens G N=H BA1 PE=1 SV=2 sp P69905 HBA_HUMAN

Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 sp P68871 HBB_HUMAN

Heparin cofactor 2 OS=Homo sapiens G N=SERPI N D1 PE=1 SV=3 sp P05546 HEP2_HUMAN

Histidine-rich glycoprotein OS=Homo sapiens GN=H RG PE=1 SV=1 sp P04196 HRG_HUMAN

Hornerin OS=Homo sapiens G N=H RN R PE=1 SV=2 sp Q86YZ3 HORN_HUMAN Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 sp P01877 IGHA2_HUMAN Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 sp P01861 IGHG4_HUMAN Ig heavy chain V-l l region WAH OS=Homo sapiens PE=1 SV=1 sp P01824 HV206_HUMAN Ig kappa chain V-l region DEE OS=Homo sapiens PE=1 SV=1 sp P01597 KV105_HUMAN Ig kappa chain V-l region WEA OS=Homo sapiens PE=1 SV=1 sp P01610 KV118_HUMAN Ig kappa chain V-l l region FR OS=Homo sapiens PE=1 SV=1 sp P01615 KV202_HUMAN Ig kappa chain V-l l region TEW OS=Homo sapiens PE=1 SV=1 sp P01617 KV204_HUMAN Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 SV=2 sp P01625 KV402_HUMAN Ig lambda chain V-l region N EW OS=Homo sapiens PE=1 SV=1 sp P01701 LV103_HUMAN Ig lambda chain V-l l l region LOI OS=Homo sapiens PE=1 SV=1 sp P80748 LV302_HUMAN Ig mu chain C region OS=Homo sapiens GN=IG H M PE=1 SV=3 sp P01871 IGHM_HUMAN Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 sp P01591 IGJ_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens

GN=ITI H2 PE=1 SV=2 sp P19823 ITIH2_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens

GN=ITI H3 PE=1 SV=2 sp Q06033 | ITIH3_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens

GN=ITI H4 PE=1 SV=4 sp Q14624 | ITIH4_HUMAN

Junction plakoglobin OS=Homo sapiens GN=J UP PE=1 SV=3 sp P14923 PLAK_HUMAN

Keratin, type I cytoskeletal 9 OS=Homo sapiens G N=KRT9 PE=1 SV=3 sp P35527 K1C9_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens G N=KRT1 PE=1 SV=6 sp P04264 K2C1_HUMAN

Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 sp P01042 KNG1_HUMAN

Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG 1 PE=1

SV=2 sp P02750 A2GL_HUMAN

Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens

GN=FKBP1A PE=1 SV=2 sp P62942 FKB1A_HUMAN

Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 sp P32119 PRDX2_HUMAN Phosphatidylinositol-glycan-specific phospholipase D OS=Homo

sapiens GN=GPLD1 PE=1 SV=3 sp P80108 PHLD_HUMAN

Pigment epithelium-derived factor OS=Homo sapiens GN=SERPI N F1

PE=1 SV=4 sp P36955 PEDF_HUMAN

Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1 sp P03952 KLKB1_HUMAN

Plasma protease CI inhibitor OS=Homo sapiens GN=SERPING 1 PE=1

SV=2 sp P05155 IC1_HUMAN

Plasma serine protease inhibitor OS=Homo sapiens GN=SERPI NA5

PE=1 SV=3 sp P05154 IPSP_HUMAN

Pregnancy zone protein OS=Homo sapiens GN=PZP PE=1 SV=4 sp P20742 PZP_HUMAN Profilin-1 OS=Homo sapiens GN=PFN 1 PE=1 SV=2 sp P07737 PROFl_HUMAN Protein AMBP OS=Homo sapiens GN=AM BP PE=1 SV=1 sp P02760 AMBP_HUMAN Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 sp P05109 S10A8_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 sp P00734 THRB_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 sp P02787 TRFE_HUMAN Thyroxine-binding globulin OS=Homo sapiens GN=SERPI NA7 PE=1

SV=2 sp P05543 THBG_HUMAN

Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 sp P02766 TTHY_HUMAN

Vitamin K-dependent protein S OS=Homo sapiens GN=PROSl PE=1

SV=1 sp P07225 PROS_HUMAN

Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 sp P25311 ZA2G_HUMAN Table 5 provides a profile of abnormalities in pathways and abnormally glycosylated proteins in a pancreatic adenocarcinoma female patient. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a pancreatic adenocarcinoma patient by the present methods.

Table 5. A profile of abnormalities in pathways and glycosylated proteins in a pancreatic adenocarcinoma female patient.

Table 6A discloses glycoproteins differentially expressed in plasma of pancreatic adenocarcinoma male patients. These glycoproteins can be used for diagnosing, monitoring and treating a pancreatic adenocarcinoma patient by the present methods. In these methods, glycoproteins of Table 6A are used as a set of biomarkers indicative of pancreatic adenocarcinoma cancer.

Table 6A. Glycoproteins differentially expressed in plasma of pancreatic adenocarcinoma cancer (PADC) male patients

Identified Proteins Accession Number Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 sp P43652 AFAM_HUMAN

Alpha-l-acid glycoprotein 1 OS=Homo sapiens G N=ORM l PE=1 SV=1 sp P02763 A1AG1_HUMAN

Alpha-l-antitrypsin OS=Homo sapiens G N=SERPINA1 PE=1 SV=3 sp P01009 A1AT_HUMAN

Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 sp P01023 A2MG_HUMAN

Apolipoprotein A-l OS=Homo sapiens GN=APOAl PE=1 SV=1 sp P02647 APOAl_HUMAN

Apolipoprotein A-ll OS=Homo sapiens G N=APOA2 PE=1 SV=1 sp P02652 APOA2_HUMAN

Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 sp P04114 APOB_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 sp P02649 APOE_HUMAN

C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1

SV=2 sp P04003 C4BPA_HU AN

Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 PE=1 SV=2 sp Q96IY4 | CBPB2_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens G N=CPN 1 PE=1

SV=1 sp P15169 CBPN_HUMAN

Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1

SV=3 sp P22792 CPN2_HUMAN

Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 sp P00450 CERU_HUMAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp P10909 CLUS_HUMAN

Complement Cls subcomponent OS=Homo sapiens G N=C1S PE=1

SV=1 sp P09871 C1S_HU AN

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 sp P01031 C05_HU AN

Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 sp P00751 CFAB_HU AN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 sp P02741 CRP_HUMAN

Desmoplakin OS=Homo sapiens G N=DSP PE=1 SV=3 sp P15924 DESP_HUMAN

EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo

sapiens GN=EFEM P1 PE=1 SV=2 sp Q12805 | FBLN3_HUMAN

Fibrinogen alpha chain OS=Homo sapiens G N=FGA PE=1 SV=2 sp P02671 FIBA_HUMAN

Fibrinogen beta chain OS=Homo sapiens G N=FGB PE=1 SV=2 sp P02675 FIBB_HUMAN

Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 sp P02679 FIBG_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 sp P02751 FINC_HUMAN

Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1

SV=1 sp Q08380 LG3BP_HU AN

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 sp P06396 GELS_HUMAN

Haptoglobin OS=Homo sapiens GN=H P PE=1 SV=1 sp P00738 HPT_HUMAN

Hornerin OS=Homo sapiens G N=H RN R PE=1 SV=2 sp Q86YZ3 HORN_HUMAN

Identified Proteins (228) Accession Number

Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 sp P01877 IGHA2_HUMAN

Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 sp P01861 IGHG4_HUMAN

Ig heavy chain V-l l l region BU R OS=Homo sapiens PE=1 SV=1 sp P01773 HV312_HUMAN

Ig kappa chain V-l region WEA OS=Homo sapiens PE=1 SV=1 sp P01610 KV118_HUMAN

Ig kappa chain V-l l region FR OS=Homo sapiens PE=1 SV=1 sp P01615 KV202_HU AN

Ig lambda chain V-l region N EW OS=Homo sapiens PE=1 SV=1 sp P01701 LV103_HU AN

Ig mu chain C region OS=Homo sapiens GN=IG H M PE=1 SV=3 sp P01871 IGHM_HUMAN

IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 sp Q9Y6R7 FCGBP_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens

GN=ITI H2 PE=1 SV=2 sp P19823 ITIH2_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens

GN=ITI H3 PE=1 SV=2 sp Q06033 ITIH3_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens sp Q14624 ITIH4_HUMAN GN=ITI H4 PE=1 SV=4

Kallistatin OS=Homo sapiens GN=SERPI NA4 PE=1 SV=3 sp P29622 KAIN_HUMAN

Keratin, type 1 cytoskeletal 9 OS=Homo sapiens G N=KRT9 PE=1 SV=3 sp P35527 K1C9_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens G N=KRT1 PE=1 SV=6 sp P04264 K2C1_HUMAN

Keratinocyte proline-rich protein OS=Homo sapiens G N=KPRP PE=1

SV=1 sp Q5T749 | KPRP_HUMAN

Kininogen-1 OS=Homo sapiens GN=KNG 1 PE=1 SV=2 sp P01042 KNG1_HUMAN

Lipopolysaccharide-binding protein OS=Homo sapiens G N=LBP PE=1

SV=3 sp P18428 LBP_HUMAN

Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens

GN=FKBP1A PE=1 SV=2 sp P62942 FKB1A_HUMAN

Phosphatidylinositol-glycan-specific phospholipase D OS=Homo

sapiens GN=GPLD1 PE=1 SV=3 sp P80108 PHLD_HUMAN

Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIG R PE=1

SV=4 sp P01833 PIGR_HUMAN

Pregnancy zone protein OS=Homo sapiens GN=PZP PE=1 SV=4 sp P20742 PZP_HUMAN

Profilin-1 OS=Homo sapiens GN=PFN 1 PE=1 SV=2 sp P07737 PROFl_HUMAN

Protein AMBP OS=Homo sapiens GN=AM BP PE=1 SV=1 sp P02760 AMBP_HUMAN

Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 sp P02787 TRFE_HUMAN

Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 SV=2 sp P35542 SAA4_HUMAN

Sex hormone-binding globulin OS=Homo sapiens GN=SH BG PE=1

SV=2 sp P04278 SHBG_HUMAN

Thyroxine-binding globulin OS=Homo sapiens GN=SERPI NA7 PE=1

SV=2 sp P05543 THBG_HUMAN

Vitamin K-dependent protein S OS=Homo sapiens GN=PROSl PE=1

SV=1 sp P07225 PROS_HUMAN

Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 sp P25311 ZA2G_HUMAN

Table 6 provides a profile of abnormalities in pathways and glycosylated proteins in a pancreatic adenocarcinoma male patient. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a pancreatic adenocarcinoma patient by the present methods.

Table 6. A profile of abnormalities in pathways and glycosylated proteins in a pancreatic adenocarcinoma male patient.

Table 7A discloses glycoproteins differentially expressed in plasma of liver cancer patients. These glycoproteins can be used for diagnosing, monitoring and treating a liver cancer patient by the present methods. In these methods, glycoproteins of Table 5A are used as a set of biomarkers indicative of liver cancer.

Table 7A. Glycoproteins differentially expressed in plasma of liver cancer patients

Identified Proteins (739) Accession Number

Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 P63261 |ACTG_HUMAN

Alpha-lB-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 P04217 |A1BG_HUMAN

Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 P04114 |APOB_HUMAN

Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 P05090 |APOD_HUMAN

Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 P02649 |APOE_HUMAN

Apolipoprotein LI OS=Homo sapiens GN=APOLl PE=1 SV=5 0147911 AP0L1_HUMAN

Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 P08519 |APOA_HUMAN

ATP-binding cassette sub-family B member 9 OS=Homo sapiens GN=ABCB9

PE=1 SV=1 9NP78 |ABCB9_HUMAN

Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 075882 |ATRN_HUMAN

C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 P04003 C4BPA_HUMAN

C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB PE=1 SV=1 P20851 C4BPB_HUMAN

Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 P00915 CAH1_HUMAN

Carboxypeptidase N catalytic chain OS=Homo sapiens GN=CPN1 PE=1 SV=1 P15169 CBPN_HUMAN

Cholesteryl ester transfer protein OS=Homo sapiens GN=CETP PE=1 SV=2 P11597 CETP_HUMAN

Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=4 P12259 FA5_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2 P00742 FA10_HUMAN

Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3 P00748 FA12_HUMAN

Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 P00488 F13A HUMAN

Complement Clq subcomponent subunit B OS=Homo sapiens GN=C1C;B PE=1

SV=3 sp I P027461 C1QBJ-IUMAN Complement Cls subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 sp P09871|C1S_HUMAN

Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 sp P01024|CO3_HUMAN

Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 sp P0C0L4|CO4A_HUMAN

Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 sp P0C0L5|CO4B_HUMAN

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 sp P01031|CO5_HUMAN

Complement component C8 beta chain OS=Homo sapiens GN=C8B PE=1 SV=3 sp P07358|CO8B_HUMAN

Complement component C9 OS=Homo sapiens GN=C9 PE=1 SV=2 sp P02748|CO9_HUMAN

Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 sp P00751|CFAB_HUMAN

Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 sp P08603|CFAH_HUMAN Complement factor H-related protein 1 OS=Homo sapiens GN=CFHR1 PE=1

SV=2 sp 03591|FHRl_HUMAN EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo sapiens

GN=EFEMP1 PE=1 SV=2 sp i2805|FBLN3_HUMAN

Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 sp 86UX7|URP2_HUMAN

Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 sp P02671|FIBA_HUMAN

Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 sp P02675|FIBB_HUMAN

Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 sp P02679|FIBG_HUMAN

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 sp P02751|FINC_HUMAN

Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 sp P22352|GPX3_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH

PE=1SV=3 sp P04406|G3P_HUMAN Hepatocyte growth factor-like protein OS=Homo sapiens GN=MST1 PE=1

SV=2 sp P26927|HGFL_HUMAN

Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 sp Q86YZ31 HORN HUMAN

Hyaluronan-binding protein 2 OS=Homo sapiens GN=HABP2 PE=1 SV=1 sp i4520|HABP2_HUMAN g alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 sp P01877|IGHA2_HUMAN g delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 sp P01880|IGHD_HUMAN g heavy chain V-l region V35 OS=Homo sapiens PE=1 SV=1 sp P23083|HV103_HUMAN g heavy chain V-l region WOL OS=Homo sapiens PE=1 SV=1 sp P01760|HV105_HUMAN g heavy chain V-ll region MCE OS=Homo sapiens PE=1 SV=1 sp P01817|HV204_HUMAN g heavy chain V-lll region BUR OS=Homo sapiens PE=1 SV=1 sp P01773|HV312_HUMAN g heavy chain V-lll region CAM OS=Homo sapiens PE=1 SV=1 sp P01768|HV307_HUMAN g heavy chain V-lll region KOL OS=Homo sapiens PE=1 SV=1 sp P01772|HV311_HUMAN g heavy chain V-lll region NIE OS=Homo sapiens PE=1 SV=1 sp P01770|HV309_HUMAN g heavy chain V-lll region TIL OS=Homo sapiens PE=1 SV=1 sp P01765|HV304_HUMAN g kappa chain V-l region Kue OS=Homo sapiens PE=1 SV=1 sp P01604|KV112_HUMAN g kappa chain V-l region Lay OS=Homo sapiens PE=1 SV=1 sp P01605|KV113_HUMAN g kappa chain V-l region Mev OS=Homo sapiens PE=1 SV=1 sp P01612|KV120_HUMAN g kappa chain V-l region Sew OS=Homo sapiens PE=1 SV=1 sp P01609|KV117_HUMAN g kappa chain V-l region WEA OS=Homo sapiens PE=1 SV=1 sp P01610|KV118_HUMAN g kappa chain V-ll region FR OS=Homo sapiens PE=1 SV=1 sp P01615|KV202_HUMAN g kappa chain V-ll region MIL OS=Homo sapiens PE=1 SV=1 sp P01616|KV203_HUMAN g kappa chain V-ll region TEW OS=Homo sapiens PE=1 SV=1 sp P01617|KV204_HUMAN g kappa chain V-lll region CLL OS=Homo sapiens PE=4 SV=2 sp P04207|KV308_HUMAN g kappa chain V-lll region IARC/BL41 OS=Homo sapiens PE=4 SV=1 sp P06311|KV311_HUMAN g kappa chain V-lll region SIE OS=Homo sapiens PE=1 SV=1 sp P01620|KV302_HUMAN g kappa chain V-lll region VG (Fragment) OS=Homo sapiens PE=1 SV=1 sp P04433|KV309_HUMAN g lambda chain V-l region NEWM OS=Homo sapiens PE=1 SV=1 sp P01703|LV105_HUMAN g lambda chain V-l region NIG-64 OS=Homo sapiens PE=1 SV=1 sp P01702|LV104_HUMAN g lambda chain V-l region VOR OS=Homo sapiens PE=1 SV=1 sp P01699|LV101_HUMAN Ig lambda chain V-ll region TRO OS=Homo sapiens PE=1 SV=1 sp P01707 | LV204_HUMAN

Ig lambda chain V-V region DEL OS=Homo sapiens PE=1 SV=1 sp P01719 | LV501_HUMAN

Ig lambda chain V-VI region SUT OS=Homo sapiens PE=1 SV=1 sp P06317 | LV603_HUMAN

Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 sp P01871 | IGHM_HUMAN

Ig mu heavy chain disease protein OS=Homo sapiens PE=1 SV=1 sp P04220 | MUCB_HUMAN Insulin-like growth factor-binding protein complex acid labile subunit

OS=Homo sapiens GN=IGFALS PE=1 SV=1 sp P35858| ALS_HUMAN

Inter-alpha-trypsin inhibitor heavy chain HI OS=Homo sapiens GN=ITIH1 PE=1

SV=3 sp P19827 | ITIH1_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1

SV=2 sp P19823 | ITIH2_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens GN=ITIH3 PE=1

SV=2 sp Q06033 | ITIH3_HUMAN

Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1

SV=4 sp i4624 | ITIH4_HUMAN

Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 sp P14923 | PLAK_HUMAN

Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 sp P35527 | K1C9_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 sp P04264 | K2C1_HUMAN

Keratinocyte proline-rich protein OS=Homo sapiens GN=KPRP PE=1 SV=1 sp Q5T749 | KPRP_HUMAN

Lipopolysaccharide-binding protein OS=Homo sapiens GN=LBP PE=1 SV=3 sp P18428 | LBP_HUMAN

Loricrin OS=Homo sapiens GN=LOR PE=1 SV=2 sp P23490 | LORI_HUMAN

Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 sp P35579 | MYH9_HUMAN

Phosphatidylinositol-glycan-specific phospholipase D OS=Homo sapiens

GN=GPLD1 PE=1 SV=3 sp P80108 | PHLD_HUMAN

Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 sp P01833 | PIGR_HUMAN

Prenylcysteine oxidase 1 OS=Homo sapiens GN=PCYOXl PE=1 SV=3 sp Q9UHG3 PCYOX_HUMAN

Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 sp P07737 | PROF1_HUMAN

Properdin OS=Homo sapiens GN=CFP PE=1 SV=2 sp P27918 | PROP_HUMAN

Protein AM BP OS=Homo sapiens GN=AMBP PE=1 SV=1 sp P02760 |AMBP_HUMAN

Protein broad-minded OS=Homo sapiens GN=TBC1D32 PE=2 SV=4 sp Q96NH3 BROMI_HUMAN

Putative V-set and immunoglobulin domain-containing-like protein

IGHV40R15-8 OS=Homo sapiens GN=IGHV40R15-8 PE=5 SV=2 sp A6NJ16 | IV4F8_HUMAN

Ras-related protein Rap-lb OS=Homo sapiens GN=RAP1B PE=1 SV=1 sp P61224 | RAP1B_HUMAN

Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1 SV=3 sp P02753 | RET4_HUMAN

Selenoprotein P OS=Homo sapiens GN=SEPP1 PE=1 SV=3 sp P49908 |SEPP1_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp 0.9 Y490 TLN 1_H U M AN

Telomere length regulation protein TEL2 homolog OS=Homo sapiens

GN=TEL02 PE=1 SV=2 sp Q9Y4R8 TEL02 H U M AN

Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 SV=3 sp P05452 |TETN_HUMAN

Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 sp P07996 |TSP1_HUMAN

Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 sp P05543 |THBG_HUMAN

Transforming growth factor-beta-induced protein ig-h3 OS=Homo sapiens

GN=TGFBI PE=1 SV=1 sp Q15582 | BGH3_HUMAN

Tubulin alpha-IB chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 sp P68363 ITBAIB HUMAN

Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 sp P02774 |VTDB_HUMAN

Vitamin K-dependent protein C OS=Homo sapiens GN=PROC PE=1 SV=1 sp P04070 | PROC_HUMAN

Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 sp P04004 |VTNC_HUMAN

Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 sp P25311 |ZA2G_HUMAN

Table 7 provides a profile of abnormalities in pathways and glycosylated proteins in a liver cancer male patient. This profile, including any of protein biomarkers and pathways, can be used for diagnosing, monitoring and treating a liver cancer patient by the present methods.

Table 7. A profile of abnormalities in pathways and glycosylated proteins in a liver cancer male patient.

As can be appreciated from the data in Tables 1A-7A and Tables 1-7, some of the protein markers associate specifically with a particular type of GI cancer, while other protein markers are common for several different GI cancers. As can be also appreciated from Tables 1A-7A and Tables 1-7, various pathways are affected in each of the cancers.

The term "biological pathway or pathway" is understood broadly and refers to a set of proteins (and other molecules) that act as a network to initiate, alter or terminate a biological process. Examples of biological pathways include metabolic pathways, gene- regulation pathways, and signal transduction pathways. Dozens and even hundreds of different proteins may comprise a pathway. An activation or inhibition of one protein in a pathway may trigger a chain reaction of activities in the pathway. While two different cancer patients may have a mutation in different proteins, the same pathway may be affected in both patients and lead to the same symptoms. Thus, identifying pathways affected in a cancer patient is a technical advantage of the present methods because it allows to more accurately assess the differences which cause symptoms.

According to some embodiments of the present methods, the first step is to identify proteins abnormally present in a blood or plasma sample of a patient in comparison to a healthy control, as shown in Tables 1 A, 2A, 3 A, 4A, 5 A, 6A, and 7 A. The second step is to identify pathways which are enriched (show statistically significantly overlap) with the proteins from the protein profile lists, as shown in Tables 1, 2, 3, 4, 5, 6 and 7.

Using the Fisher's exact test, nonrandom associations between two categorical variables (a pathway and a protein profile list) are determined. Each of the protein profile lists is compared to a pathway database by applying Fisher's exact test consecutively to all pathways in the database to compare the given protein profile and each of the pathways in the database. One pathway database of pathway maps that can be used for this analysis is PATHWAY STUDIO ^R available from Elsevier, Inc. (Nikitin et al. 2003, Bioinformatics, https://www.elsevier.com/solutions/pathway-studio-biological -research).

This approach was used to identify pathways for glycosylated protein biomarkers in Tables 1 -7. PATHWAY STUDIO ^R software was also used to generate Figures 1-23, each of which defines a relationship between proteins in a pathway affected in at least one of GI cancers. Any of the proteins shown in Figs. 1 -23 can be included as an additional biomarker for diagnosing, monitoring and/or treating a GI cancer together with protein biomarkers from Tables 1-7.

Table 8 provides a list of pathways which can be used as a biomarker in screening, monitoring and/or treating a GI cancer. In Table 8, a pathway that can be used as a biomarker in colorectal cancer, gastric cancer, liver cancer or pancreatic cancer is identified with an XX.

As can be seen from Table 8, some pathways, such as for example, the adherens junction assembly pathway (Fig. 1) is a specific biomarker for a gastric cancer female patient, while other pathways such as the coagulation cascade pathway (Fig. 3) is a biomarker for all GI cancers, including colorectal cancer, gastric cancer, liver cancer and pancreatic cancer. Table 8 matches each of the pathways with a figure from Figs. 1 -23. Table 8. Summary of pathways of glycobiomarkers of GI cancers

19 Protein Folding 19 XX XX

Scavenger

20 Receptors in 20 XX XX XX XX XX Platelet Activation

Scavenger

Receptors in

21 21 XX XX XX XX Platelet

Aggregation

TAM Receptors in

22 Platelet 22 XX XX XX XX

Aggregation

Vascular

Endothelial Cell

23 Activation by 23 XX Blood Coagulation

Factors

M - Male; F - Female

XX - denotes that the pathway is affected.

Each of the pathways listed in Table 8 (as defined in more detail in Figs. 1-23 by proteins which play a role in the pathway) can be used as a biomarker in a number of various tests. Various proteins from each of the pathway, including those listed in tables 1- 7 and other proteins as shown in Figs. 1-23, can be included as representative biomarkers in screening, monitoring and treating GI cancer patients.

Further embodiments provide diagnostic methods based on any of the biomarkers in Tables 1, 2, 3, 4, 5, 6, 7 and/or 8, as may be further modified based on Figs. 1- 23. Various methods are contemplated and may include an immunoassay, biochip assay, nanoassay in which at least one panel with at least one or more biomarkers from Tables 1-8 is used, as may be further modified with any of additional protein biomarkers shown in Figs. 1- 23.

At least in some of these methods, a sample is obtained from a patient. This sample may be a human tissue biopsy or biosample including pancreas biopsy sample, gastrointestinal sample, blood sample, plasma sample, serum sample, circulating tumor cells sample, tear sample, saliva sample, sperm sample, urine sample, fecal sample and hair sample or any other human biospecimen. The sample is then screened to obtain a protein profile and to determine whether the protein profile in the sample matches at least partially a profile from any of Tables 1, 2, 3, 4, 5, 6, or 7. The abnormal proteins in the patient's profile are also analyzed to determine which of the pathways are affected, including the pathways shown in Tables 1-8. Suitable screening methods may include chromatography, gas chromatography, liquid chromatography, mass spectrometry, ELISA, antibody linkage, immunoassay, biochip assay, microarray, nanoassay, spectroscopy, a multiplex molecular assay or techniques which utilize a fluorescent, enzyme, radioactive, metallic, biotin, chemiluminescent, bioluminescent molecule assay. Suitable methods further include a combination of a detection techniques of nucleic acids and proteins or peptides.

In some methods, at least one biomarker and/or glycobiomarker of Tables 1-8 is immobilized on a solid support. In some methods, the testing is conducted by reacting the patient's sample with at least one anybody or protein chemistry based reagent specific to at least one biomarker and/or glycobiomarker of Tables 1-8.

In further embodiments, the testing is conducted by reacting the patient's sample with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 1-8. In some embodiments, the testing is conducted by reacting the patient's sample with a synthetic compound or probe which reacts with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 1-8.

Further embodiments include a method for diagnosing, monitoring and reating a GI cancer, the method comprising obtaining a blood or plasma sample from a patient in need of the treatment, analyzing glycoproteins in the sample, creating a profile of pathways and glycoproteins for the patient, and comparing the profile to the profiles of glycobiomarkers and pathways of Tables 1-8.

In some embodiments, a screening can be conducted with a patient's sample without protein extraction. In further embodiments, proteins are isolated from the patient's sample, such as a blood or plasma sample, and a test is conducted with the isolated proteins. In some embodiments, all proteins in the sample are analyzed. In other embodiments, the analysis is conducted only for proteins which are glycosylated. In further embodiments, only GlcNac glycosylated proteins are analyzed.

The advantages of these screening methods include: these tests are noninvasive and they can be conducted in a very short period of time. In some embodiments, the same test can be repeated several times within a period of time to monitor progression of a GI cancer and/or evaluate the efficiency of a treatment plan.

Further embodiments provide Multiplex Molecular Diagnostic Protein assays, a combination of protein assay and assay based on detection of DNA or RNA, and kits, including an immunoassay, biochip assay, nanoassay and molecular assay. In some embodiments, an assay detects protein biomarker and/or glycobiomarkers or peptides derived from the biomarker and/or glycobiomarkers from any of Tables 1-8 and Figs. 1-24.

In further embodiments, a patient's sample is reacted with a set of antibodies, each of which is selectively specific for at least one biomarker and/or glycobiomarker from Tables 1 , 2, 3, 4, 5, 6, 7 or 8. The complex between an antibody and a glycobiomarker or a biomarker is then may be detected with a second antibody conjugated to a detection molecule.

Further embodiments include methods for detecting and monitoring a GI cancer. In these methods, a patient's sample is tested for expression of at least some biomarker and/or glycobiomarkers listed in Table 2, 3, 4, 5, 6, 7 or 8.

Further embodiments include methods in which patient's response to therapy, such as for example surgery, radiation, immunotherapy or chemotherapy, is monitored with testing a patient's sample for expression of at least some biomarker and/or glycobiomarkers listed in Tables 1 , 2, 3, 4, 5, 6, 7 and 8. Other applications include detecting a recurrent or residual GI cancer by testing a patient's sample for expression of at least some biomarker and/or glycobiomarkers listed in Tables 1 , 2, 3, 4, 5, 6 and/or 7.

Other applications include screening of genetically predisposed individuals for a GI caner by testing the individual's sample for expression of at least some biomarkers and/or glycobiomarkers listed in Tables 1 , 2, 3, 4, 5, 6 and/or 7. Such genetically predisposed individuals include, but not limited, to BRCA mutation carriers; PALB2 mutation carriers; pi 6 mutation carriers; Lynch syndrome patients; Peutz-Jeghers syndrome patients; and individuals with a family history of a GI cancer.

In some methods, a biochip comprising a set of at least one or more biomarker and/or glycobiomarkers listed in Tables 1 , 2, 3, 4, 5, 6 and/or 7 can be used as a robust and sensitive tool to monitor a GI cancer progression and response to therapy. These biochips can be also used as a biomarker or molecular modality for drug development or drug optimization.

In some embodiments, a patient can be screened and evaluated based on a test conducted with the patient's sample and a panel of biomarker and/or glycobiomarkers and pathways which include at least one or more biomarkers listed in Tables 1, 2, 3, 4, 5, 6, 7 and/or 8.

This invention also provides compositions and methods for selective detection of pancreatic diseases and/or disorders of the pancreas, including pancreatic cancer, pancreatitis, acute pancreatitis, chronic pancreatitis, hereditary pancreatitis, autoimmune pancreatitis, and pancreatic neoplasm. It also provides compositions and methods for monitoring progression of a pancreatic disease and/or disorder of the pancreas, including, but not limited to, pancreatic cancer, pancreatitis, and autoimmune pancreatitis

The invention provides a panel of pancreatic disease biomarkers. These biomarkers may include glycosylated biomarkers. In some embodiments, a panel of biomarkers include at least one or more glycosylated biomarkers listed in Tables 5A, 5, 6A, and 6. In other embodiments, a panel of biomarkers include all biomarkers listed in Tables 5A, 5, 6A, and 6. Further embodiments include a panel which comprises at least one or more biomarkers as listed in Table 9. In further embodiments, a panel includes a combination of at least one or more biomarkers from Table 9 and at least one or more biomarkers from any of the tables 5A, 5, 6A, and 6.

In some embodiments, a panel of biomarkers includes at least one or more proteins listed in Table 9. In other embodiments, a panel of biomarkers includes all proteins listed in Table 9. Further embodiments include a panel which comprises at least one or more glycosylated biomarkers as listed in any of the Tables 5 A, 5, 6A, and 6.. In further embodiments, a panel includes a combination of at least one or more biomarkers from Tables 5A, 5, 6A, 6 and 9.

Table 9. Proteins differentially expressed in human plasma of pancreatic adenocarcinoma patients

14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1

SV=2 sp P61981 1433G. H UMAN

14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1

SV=1 sp P63104 1433Z_ H U MAN

78 kDa glucose-regulated protein OS=Homo sapiens

GN=HSPA5 PE=1 SV=2 sp P11021 G RP78 _HU MAN

Actin, cytoplasmic 2 OS=Homo sapiens G N=ACTG1 PE=1 SV=1 sp P63261 ACTG_ H U MAN

Alpha-l-acid glycoprotein 2 OS=Homo sapiens GN=ORM2

PE=1 SV=2 sp P19652 A1AG2 _H UMAN

Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1

SV=3 sp P01023 A2MG_ .H UMAN

Alpha-actinin-1 OS=Homo sapiens G N=ACTN 1 PE=1 SV=2 sp P12814 ACTN 1 _H U MAN

Alpha-enolase OS=Homo sapiens GN=EN01 PE=1 SV=2 sp P06733 ENOA_ H U MAN

Alpha-N-acetylglucosaminidase OS=Homo sapiens

GN=NAGLU PE=1 SV=2 sp P54802 ANAG_ HU MAN

Aminopeptidase N OS=Homo sapiens GN=AN PEP PE=1 SV=4 sp P15144 AM PN_ .H UMAN

Angiogenin OS=Homo sapiens GN=ANG PE=1 SV=1 sp P03950 ANGI_H U MAN

Apolipoprotein A-l OS=Homo sapiens GN=APOAl PE=1 SV=1 sp P02647 APOA1 _H U MAN

Apolipoprotein A-ll OS=Homo sapiens G N=APOA2 PE=1 SV=1 sp P02652 APOA2 _H U MAN

Apolipoprotein C-l l l OS=Homo sapiens GN=APOC3 PE=1 SV=1 sp P02656 APOC3 _H U MAN Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1 sp P55056|APOC4_HUMAN

Apolipoprotein F OS=Homo sapiens GN=APOF PE=1 SV=2 sp Q13790|APOF_HUMAN

Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 sp P61769|B2MG_HUMAN

Beta-enolase OS=Homo sapiens GN=EN03 PE=1 SV=5 sp P13929|ENOB_HUMAN

Cadherin-5 OS=Homo sapiens GN=CDH5 PE=1 SV=5 sp P33151|CADH5_HUMAN

Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 sp P62158|CALM_HUMAN

Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 sp P27797|CALR_HUMAN

Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 sp P00915|CAH1_HUMAN

Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 sp P00918|CAH2_HUMAN Cartilage oligomeric matrix protein OS=Homo sapiens

GN=COMP PE=1 SV=2 sp P49747|COMP_HUMAN

Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 sp P04040|CATA_HUMAN

Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 sp P07339|CATD_HUMAN

CD5 antigen-like OS=Homo sapiens GN=CD5L PE=1 SV=1 sp 0438661 CD5L_HUMAN Cell surface glycoprotein MUC18 OS=Homo sapiens

GN=MCAM PE=1 SV=2 sp P43121|MUC18_HUMAN Chloride intracellular channel protein 1 OS=Homo sapiens

GN=CLIC1 PE=1SV=4 sp 0002991 CLIC1_HU MAN

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp P10909|CLUS_HUMAN

Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2 sp P00742|FA10_HUMAN

Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3 sp P00748|FA12_HUMAN

Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 sp P23528|C0F1_HUMAN

Collectin-10 OS=Homo sapiens GN=COLEC10 PE=2 SV=2 sp Q9Y6Z7|COL10_HUMAN

Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 sp P0C0L5|CO4B_HUMAN

Coronin-IA OS=Homo sapiens GN=COR01A PE=1 SV=4 sp P31146|C0R1A_HUMAN Corticosteroid-binding globulin OS=Homo sapiens

GN=SERPINA6 PE=1 SV=1 sp P08185|CBG_HUMAN

C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 sp P02741|CRP_HUMAN Creatine kinase M-type OS=Homo sapiens GN=CKM PE=1

SV=2 sp P06732|KCRM_HUMAN

Cystatin-C OS=Homo sapiens GN=CST3 PE=1 SV=1 sp P01034|CYTC_HUMAN Cysteine-rich secretory protein 3 OS=Homo sapiens

GN=CRISP3 PE=1SV=1 sp P54108|CRIS3_HUMAN EGF-containing fibulin-like extracellular matrix protein 1

OS=Homo sapiens GN=EFEMP1 PE=1 SV=2 sp Q12805|FBLN3_HUMAN Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3

PE=1SV=1 sp Q86UX7|URP2_HUMAN

Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 sp P02671|FIBA_HUMAN

Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 sp P02675|FIBB_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1

SV=3 sp P02679|FIBG_HUMAN

Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 sp P21333|FLNA_HUMAN Flavin reductase (NADPH) OS=Homo sapiens GN=BLVRB PE=1

SV=3 sp P30043|BLVRB_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens

GN=ALDOA PE=1 SV=2 sp P04075|ALDOA_HUMAN Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP

PE=1SV=1 sp Q08380|LG3BP_HUMAN

Gamma-glutamyl hydrolase OS=Homo sapiens GN=GGH PE=1 sp Q92820|GGH_HUMAN SV=2

Glutathione S-transferase omega-1 OS=Homo sapiens

GN=GST01 PE=1 SV=2 sp I P784171 GST01_H U M AN

Glyceraldehyde-3-phosphate dehydrogenase OS=Homo

sapiens GN=GAPDH PE=1 SV=3 sp|P04406|G3P_HUMAN

Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 sp|P00738|HPT_HUMAN

Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1

SV=2 sp|P69905|HBA_HUMAN

Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1

SV=2 sp|P68871|HBB_HUMAN

Hepatocyte growth factor-like protein OS=Homo sapiens

GN=MST1 PE=1 SV=2 sp|P26927|HGFL_HUMAN

Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3

PE=1 SV=2 sp|P01860|IGHG3_HUMAN

Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1

SV=1 sp|P01834|IGKC_HUMAN

Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 sp|P01871|IGHM_HUMAN Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens sp|B9A064|IGLL5_HUMAN GN=IGLL5 PE=2SV=2 (+4)

Insulin-like growth factor II OS=Homo sapiens GN=IGF2 PE=1

SV=1 sp|P01344|IGF2_HUMAN

Insulin-like growth factor-binding protein 3 OS=Homo sapiens

GN=IGFBP3 PE=1 SV=2 sp|P17936|IBP3_HUMAN

Intercellular adhesion molecule 1 OS=Homo sapiens

GN=ICAM1 PE=1SV=2 sp| P053621 ICAM1_HUMAN

Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1

PE=1 SV=6 sp|P04264|K2Cl_HUMAN

Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens

GN=KRT2 PE=1SV=2 sp|P35908|K22E_HUMAN

L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA

PE=1 SV=2 sp I P00338| LDHA_HUMAN

L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB

PE=1 SV=2 sp|P07195|LDHB_HUMAN

Lysosome-associated membrane glycoprotein 1 OS=Homo

sapiens GN=LAMP1 PE=1 SV=3 sp I P11279| LAMP1_HUMAN Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 sp|P61626|LYSC_HUMAN Mannan-binding lectin serine protease 2 OS=Homo sapiens

GN=MASP2 PE=1 SV=4 sp|O00187|MASP2_HUMAN

Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA

OS=Homo sapiens GN=MAN1A1 PE=1 SV=3 sp| P33908| MA1A1_HUMAN

Multiple epidermal growth factor-like domains protein 8

OS=Homo sapiens GN=MEGF8 PE=1 SV=2 sp|Q7Z7M0|MEGF8_HUMAN

Neural cell adhesion molecule 1 OS=Homo sapiens

GN=NCAM1 PE=1 SV=3 sp|P13591|NCAMl_HUMAN

Neural cell adhesion molecule Ll-like protein OS=Homo

sapiens GN=CHL1 PE=1 SV=4 sp| 0005331 CHL1_HUMAN

Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 sp|P59665|DEFl_HUMAN SV=1 (+1)

Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 sp|P32119|PRDX2_HUMAN Phosphatidylinositol-glycan-specific phospholipase D

OS=Homo sapiens GN=GPLD1 PE=1 SV=3 sp|P80108|PHLD_HUMAN Pigment epithelium-derived factor OS=Homo sapiens

GN=SERPINF1 PE=1SV=4 sp|P36955|PEDF_HUMAN

Plasma alpha-L-fucosidase OS=Homo sapiens GN=FUCA2

PE=1 SV=2 sp Q9BTY2|FUC02_HUMAN

Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1 sp P03952|KLKB1_HUMAN

Platelet glycoprotein lb alpha chain OS=Homo sapiens

GN=GP1BA PE=1SV=1 sp P07359|GP1BA_HUMAN

Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3 sp P08567|PLEK_HUMAN

Pregnancy zone protein OS=Homo sapiens GN=PZP PE=1

SV=4 sp P20742|PZP_HUMAN

Procollagen C-endopeptidase enhancer 1 OS=Homo sapiens

GN=PCOLCE PE=1SV=2 sp Q15113|PC0C1_HUMAN

Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 sp P05109|S10A8_HUMAN

Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM

PE=1 SV=4 sp P14618|KPYM_HUMAN

Ras suppressor protein 1 OS=Homo sapiens GN=RSU1 PE=1

SV=3 sp Q15404|RSU1_HUMAN

Receptor-type tyrosine-protein phosphatase eta OS=Homo

sapiens GN=PTPRJ PE=1 SV=3 sp Q12913|PTPRJ_HUMAN

Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1

SV=3 sp P02753|RET4_HUMAN

Scavenger receptor cysteine-rich type 1 protein M130

OS=Homo sapiens GN=CD163 PE=1 SV=2 sp Q86VB71 C163A_H U M AN

Secreted phosphoprotein 24 OS=Homo sapiens GN=SPP2

PE=1 SV=1 sp Q13103|SPP24_HUMAN

Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 sp P02787|TRFE_HUMAN

Sex hormone-binding globulin OS=Homo sapiens GN=SHBG

PE=1 SV=2 sp P04278|SHBG_HUMAN

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp Q9Y490|TLN1_HUMAN

Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 sp P37802|TAGL2_HUMAN

Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1

SV=3 sp P60174|TPIS_HUMAN

Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4

PE=1 SV=3 sp P67936|TPM4_HUMAN

Vasodilator-stimulated phosphoprotein OS=Homo sapiens

GN=VASP PE=1 SV=3 sp P50552|VASP_HUMAN

Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 sp P18206|VINC_HUMAN

Vitamin K-dependent protein S OS=Homo sapiens GN=PROSl

PE=1 SV=1 sp|P07225|PROS_HUMAN

Other embodiments provide kits which comprise at least one panel as described above in connection with Tables 5A, 5, 6A, 6 and 9. Such kits may further comprise a biochip.

Various methods are contemplated and may include an immunoassay, biochip assay, nanoassay in which at least one panel with at least one or more biomarkers from Tables 5A, 5, 6A and 6 or at least one or more biomarkers from Table 9 are used. At least in some of these methods, a sample is obtained from a patient. This sample may be a human tissue biopsy or biosample including pancreas biopsy sample, gastrointestinal sample, blood sample, plasma sample, serum sample, circulating tumor cells sample, tear sample, saliva sample, sperm sample, urine sample, fecal sample and hair sample or any other human biospecimen.

The sample is then screened for presence of at least one or more glycosylated markers listed in Tables 5A, 5, 6A, 6 and/or for presence of at least one or more protein markers listed in Table 9.

Suitable screening methods may include chromatography, gas chromatography, liquid chromatography, mass spectrometry, ELISA, antibody linkage, immunoassay, biochip assay, microarray, nanoassay, spectroscopy, a multiplex molecular assay or techniques which utilize a fluorescent, enzyme, radioactive, metallic, biotin, chemiluminescent, bioluminescent molecule assay. Suitable methods further include a combination of a detection techniques of nucleic acids and proteins or peptides. In some methods, at least one biomarker and/or glycobiomarker of Tables 5A, 5, 6A, 6 and 9 is immobilized on a solid support. In some methods, the testing is conducted by reacting the patient's sample with at least one anybody or protein chemistry based reagent specific to at least one biomarker and/or glycobiomarker of Tables 5A, 5, 6A, 6 and 9. In further embodiments, the testing is conducted by reacting the patient's sample with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 5 A, 5, 6A, 6 and 9. In some embodiments, the testing is conducted by reacting the patient's sample with a synthetic compound or probe which react with at least one protein specific to at least one biomarker and/or glycobiomarker of Tables 5 A, 5, 6A, 6 and 9.

Further embodiments include a method for treating a disorder of the pancreas, the method comprising obtaining a sample from a mammal in need of the treatment and testing the sample for at least one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9.

A method is provided for determining a state or probability of a pancreatic disorder, the method comprising: (a) determining the level of one or more biomarker and/or glycobiomarker selected from Tables 5 A, 5, 6A, 6 and 9, and (b) the level of CA 19-9.

A method is provided for determining a state or probability of a pancreatic disorder, the method comprising: (a) determining the level of one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9 and (b) the level of amylase. A method is provided for determining a state or probability of a pancreatic disorder, the method comprising: (a) determining the level of one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9, and (b) the level of glycosylated protein.

A method is provided for determining a state or probability of a pancreatic disorder, the method comprising: (a) determining the level of one or more biomarker and/or glycobiomarker selected from Tables 5 A, 5, 6A, 6 and 9, and (b) the level of RNA or DNA.

A method is provided for determining a state or probability of a pancreatic disorder, the method comprising: (a) determining the level of one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9, and (b) the level of virus or viral infection of the patient.

In some embodiments, a screening can be conducted with a patient's sample without protein extraction. In further embodiments, proteins are extracted from the patient's sample and a test is conducted with the extracted proteins. In some embodiments, all proteins in the sample are analyzed. In other embodiments, the analysis is conducted only for proteins which are abnormally glycosylated.

The advantages of these screening methods include: these tests are noninvasive and they can be conducted in a very short period of time. In some embodiments, the same test can be repeated several times within a period of time to monitor progression of a pancreatic disease and/or access the efficiency of a treatment plan.

Further embodiments provide Multiplex Molecular Diagnostic Protein assays, a combination of protein assay and assay based on detection of DNA or RNA, and kits, including an immunoassay, biochip assay, nanoassay and molecular assay. In some embodiments an assay detects protein biomarker and/or glycobiomarkers or peptides derived from the biomarker and/or glycobiomarkers from Tables 5A, 5, 6A, and 6. In other embodiments, an assay detects biomarkers or peptides derived from biomarkers from Table 9. In other embodiments, an assay detects biomarkers or peptides derived from biomarkers from Table 9. In other embodiments, an assay detects biomarkers or peptides derived from biomarkers from Table 9.

In further embodiments, a patient's sample is reacted with a set of antibodies, each of which is selectively specific for at least one biomarker and/or glycobiomarker from Tables 5A, 5, 6A, 6 and 9. The complex between an antibody and a glycobiomarker or a biomarker is then may be detected with a second antibody conjugated to a detection molecule. Further embodiments include methods for detecting and monitoring a pancreatic disease, including pancreatic cancer, pancreatitis, and autoimmune pancreatitis. In these methods, a patient's sample is tested for expression of at least some biomarker and/or glycobiomarkers listed in Tables 5A, 5, 6A, 6 and 9. Further embodiments include methods in which patient's response to therapy is monitored with testing a patient's sample for expression of at least some biomarker and/or glycobiomarkers listed in Tables 5A, 5, 6A, 6 and 9. Other applications include detecting a recurrent or residual pancreatic disease by testing a patient's sample for expression of at least some biomarker and/or glycobiomarkers listed in Tables 5A, 5, 6A, 6 and 9.

Other applications include screening of genetically predisposed individuals for a pancreatic disease by testing the individual's sample for expression of at least some biomarkers and/or glycobiomarkers listed in Tables 5A, 5, 6A, 6 and 9. Such genetically predisposed individuals include, but not limited, to BRCA mutation carriers; PALB2 mutation carriers; pi 6 mutation carriers; Lynch syndrome patients; Peutz-Jeghers syndrome patients; and individuals with a family history of pancreatic cancer cases.

In some methods, a biochip comprising a set of at least one or more biomarker and/or glycobiomarkers listed in Tables 5A, 5, 6A, 6 and 9 can be used as a robust and sensitive tool to monitor disease progression and response to therapy. These biochips can be also used as a biomarker or molecular modality for drug development or drug optimization.

Other applications include tests conducted for detection and measurement of biomarker and/or glycobiomarkers which include at least one or more biomarkers listed in Tables 5A, 5, 6A, 6 and 9. Such tests may include verification and support of clinical and operative decision-making process and management of pancreatic cyst neoplasms.

Further embodiments provide methods for treating a disorder of the pancreas, the method comprising obtaining a sample from a mammal in need of the treatment and testing the sample for at least one or more biomarker and/or glycobiomarker selected from Tables 5A, 5, 6A, 6 and 9.

The invention will be now further explained by the following non-limiting examples. Example 1.

Human plasma was obtained from cancer patients. Human plasma samples from healthy control individuals were used as controls. All patients and control individuals have provided informed consent, and collection of human samples was approved by the local Review Board. Glycosylated forms of proteins were isolated from human plasma as it has been described before (Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. "Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain". PNAS 2004 Sep 7;101(36): 13132-7. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA 3rd, Peters EC, Driggers EM, Hsieh-Wilson LC. "Phosphofructokinase 1 glycosylation regulates cell growth and metabolism". Science. 2012 Aug 24;337(6097):975- 80.) Then isolated glycosylated forms of proteins from human plasma were used for the proteomics analysis.

Mass Spectrometry of protein expression profiling was performed according to the established protocol. Briefly, each isolated sample was processed by SDS-PAGE, using a 10% Bis-Tris NuPAGE gel (Invitrogen) with the MES buffer system. The entire mobility region was excised and processed by in-gel digestion using a robot (ProGest, DigiLab) with the following protocol: washed with 25mM ammonium bicarbonate followed by acetonitrile; reduced with lOmM dithiothreitol at 60°C followed by alkylation with 50mM iodoacetamide at RT. digested with trypsin (Promega) at 37°C for 4h, quenched with formic acid and the supernatant was analyzed directly without further processing. Mass Spectrometry of each digested sample was analyzed by nano LC-MS/MS with a ThermoFisher EASY-nLC 1000 HPLC system interfaced to a ThermoFisher Q Exactive mass spectrometer.

A sample was then loaded on a trapping column and eluted over a 75 μιτι x 150mm analytical column (Thermo Fisher P/N 164568) at 300nL/min using a 4hr reverse phase gradient; both columns were packed with Acclaim PepMap 100 A, 3 3 μιτι resin (Thermo Scientific). The mass spectrometer was operated in the data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 and 17,500 FWHM resolution respectively. The fifteen most abundant ions were selected for MS/MS. The data processing was analyzed using a Mascot. Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a nonredundant list per sample. The data was filtered using at 1% protein and peptide FDR and requiring at least two unique peptides per protein.

The list of proteins was then additionally analyzed with the ELSVIER PATHWAY STUDIO software.

Example 2.

Human plasma was obtained from cancer patients. Human plasma samples from healthy control individuals were used as controls. All patients and control individuals have provided informed consent, and collection of human samples was approved by the local Review Board. ΙΟμί of each plasma sample was processed using the Multiple Affinity Removal System (MARS specific for the 14 most abundant human plasma proteins (Agilent (P/N5188-6560)). The sample was processed using the vendor protocol. Depleted samples were buffer exchanged against HPLC grade water and quantified by Qubit fluorometry at a 1: 10 dilution and % depletion was assessed. 20μg of each sample was digested with trypsin using the following protocol: reduced with lOmM dithiothreitol at 60°C for 30 minutes in 25mM Ammonium bicarbonate; alkylated with iodoacetamide for at 60°C for 45 minutes in 25mM Ammonium bicarbonate; digested overnight with sequencing grade trypsin at 37°C, enzyme: substrate ratio 1 :20; quenched with formic acid. Digested samples were desalted using a Waters HLB μΕΙώίοη plate per the vendor protocol. Desalted samples were suspended in ΙΟΟμί of 0.1% TFA for analysis.

Mass Spectrometry of protein expression profiling was performed according to the established protocol. Briefly, each isolated sample was processed by SDS-PAGE, using a 10% Bis-Tris NuPAGE gel (Invitrogen) with the MES buffer system. The entire mobility region was excised and processed by in-gel digestion using a robot (ProGest, DigiLab) with the following protocol: washed with 25mM ammonium bicarbonate followed by acetonitrile; reduced with lOmM dithiothreitol at 60°C followed by alkylation with 50mM iodoacetamide at RT. digested with trypsin (Promega) at 37°C for 4h, quenched with formic acid and the supernatant was analyzed directly without further processing. Mass Spectrometry of each digested sample was analyzed by nano LC-MS/MS with a ThermoFisher EASY-nLC 1000 HPLC system interfaced to a ThermoFisher Q Exactive mass spectrometer.

A sample was then loaded on a trapping column and eluted over a 75μιη x 150mm analytical column (Thermo Fisher P/N 164568) at 300nL/min using a 4hr reverse phase gradient; both columns were packed with Acclaim PepMap 100 A, 3 3 μιτι resin (Thermo Scientific). The mass spectrometer was operated in the data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 and 17,500 FWHM resolution respectively. The fifteen most abundant ions were selected for MS/MS. The data processing was analyzed using a Mascot. Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a nonredundant list per sample. The data was filtered using at 1% protein and peptide FDR and requiring at least two unique peptides per protein. A List of Abbreviations for Figs. 1-23 and Tables 1, 2, 3, 4, 5, 6, 7 and 8

Adherens Junction Assembly (Nectin)

SSX2IP synovial sarcoma, X breakpoint 2 interacting protein

Bradykinin Effects in Inflammation

NFKBIA NFKB inhibitor alpha

NOS3 nitric oxide synthase 3

NOS2 nitric oxide synthase 2

PDPK1 3-phosphoinositide dependent protein kinase 1

PLAT plasminogen activator, tissue type

PLAU plasminogen activator, urokinase

PLAUR plasminogen activator, urokinase receptor

PLG plasminogen

PLCB3 phospholipase C beta 3

PRKCQ protein kinase C theta

MAP2K3 mitogen-activated protein kinase kinase 3

MAP2K6 mitogen-activated protein kinase kinase 6

RAC1 ras-related C3 botulinum toxin substrate 1

(rho family, small GTP binding protein Racl)

XPNPEP2 X-prolyl aminopeptidase (aminopeptidase

P) 2, membrane-bound

PTGES prostaglandin E synthase

PLCB1 phospholipase C beta 1

Coagulation Cascade

Name Description

SERPINC1 serpin family C member 1

F2 coagulation factor II, thrombin

F5 coagulation factor V F9 coagulation factor IX

Fll coagulation factor XI

F10 coagulation factor X

F3 coagulation factor III, tissue factor

F12 coagulation factor XII

F13A1 coagulation factor XIII A chain

F8 coagulation factor VIII

F7 coagulation factor VII

KLKB1 kallikrein B 1

KNG1 kininogen 1

PLAT plasminogen activator, tissue type

PLG plasminogen

PROC protein C, inactivator of coagulation factors Va and Villa

PROS1 protein S (alpha)

TFPI tissue factor pathway inhibitor

THBD thrombomodulin

PROZ protein Z, vitamin K dependent plasma glycoprotein

FGL2 fibrinogen like 2

SERPINA10 serpin family A member 10

VKORC1 vitamin K epoxide reductase complex subunit 1

Complement Activation by Lectin

Name Description

C3 complement component 3

C4B complement component 4B (Chido blood group)

C2 complement component 2 C3AR1 complement component 3a receptor 1

C5 complement component 5

C5AR1 complement component 5a receptor 1

C8A complement component 8 alpha subunit

C6 complement component 6

C9 complement component 9

C7 complement component 7

MBL2 mannose binding lectin 2

MASP1 mannan binding lectin serine peptidase 1

MASP2 mannan binding lectin serine peptidase 2

C5AR2 complement component 5a receptor 2

Complement Activation in Macular Degeneration

C9 complement component 9

C7 complement component 7

CLU clusterin

CR1 complement component 3b/4b receptor

1 (Knops blood group)

CRP C-reactive protein, pentraxin-related

CD55 CD55 molecule (Cromer blood group)

CFD complement factor D (adipsin)

CFHR1 complement factor H related 1

CFH complement factor H

CFI complement factor I

MBL2 mannose binding lectin 2

CD46 CD46 molecule

CFP complement factor properdin

MASP1 mannan binding lectin serine peptidase

1

HTRA1 HtrA serine peptidase 1

TIMP3 TIMP metallopeptidase inhibitor 3

VTN vitronectin

MASP2 mannan binding lectin serine peptidase

2

CFHR3 complement factor H related 3

Complement Alternative Pathway

Name Description

CFB complement factor B

C3 complement component 3

C5 complement component 5

C5AR1 complement component 5 a receptor 1 C8A complement component 8 alpha subunit

C6 complement component 6

C9 complement component 9

C7 complement component 7

CR2 complement component 3d receptor 2

CFD complement factor D (adipsin)

CFH complement factor H

CFI complement factor I

CFP complement factor properdin

C5AR2 complement component 5a receptor 2

Complement Cascade Activation by Pentraxins

FCGR3A Fc fragment of IgG receptor Ilia

CFH complement factor H

MBL2 mannose binding lectin 2

MASP1 mannan binding lectin serine

peptidase 1

PTX3 pentraxin 3

SNRNP70 small nuclear ribonucleoprotein Ul subunit 70

SNRPN small nuclear ribonucleoprotein polypeptide N

Complement Classical Pathway

Name Description

C3 complement component 3

C4B complement component 4B (Chido blood group)

C2 complement component 2

C1R complement Clr subcomponent

CIS complement component 1, s

subcomponent

C3AR1 complement component 3 a receptor 1

C5 complement component 5

C5AR1 complement component 5 a receptor 1

C8A complement component 8 alpha subunit

C6 complement component 6

C9 complement component 9

C7 complement component 7

C5AR2 complement component 5 a receptor 2 Focal Junction Assembly

PIP5K1C phosphatidylinositol-4-phosphate 5- kinase type 1 gamma

FBLIM1 filamin binding LIM protein 1

PARVA parvin alpha

Glycolysis

Histidine-Rich Glycoprotein (HRG)

Name Description

SERPINC1 serpin family C member 1

CASP3 caspase 3

CD36 CD36 molecule F12 coagulation factor XII

FGF2 fibroblast growth factor 2

SERPIND1 serpin family D member 1

HRG histidine rich glycoprotein

IFNG interferon, gamma

IL2 interleukin 2

SERPINA5 serpin family A member 5

PLG plasminogen

THBS1 thrombospondin 1

THBS2 thrombospondin 2

HPSE heparanase

ADAMTSL1 ADAMTS like 1

Lipogenesis Regulation in Adipocytes

PPARA peroxisome proliferator activated receptor alpha

SCD stearoyl-CoA desaturase (delta-9- desaturase)

SLC2A1 solute carrier family 2 member 1

SLC2A4 solute carrier family 2 member 4

SREBF1 sterol regulatory element binding transcription factor 1

IRS2 insulin receptor substrate 2

DGAT1 diacylglycerol O-acyltransferase 1

AGPAT2 l-acylglycerol-3-phosphate 0- acyltransferase 2

LPIN1 lipin 1

DGAT2 diacylglycerol O-acyltransferase 2

GPAT3 glycerol-3-phosphate acyltransferase

3

SLC27A1 solute carrier family 27 member 1

Microtubule Cvtoskeleton

Name Description

DIAPH1 diaphanous related formin 1

DPYSL2 dihydropyrimidinase like 2

STMN1 stathmin 1

MAP2 microtubule associated protein 2

MAP4 microtubule associated protein 4

MAPT microtubule associated protein tau

CLIPl CAP-Gly domain containing linker protein 1

AURKB aurora kinase B

KIF14 kinesin family member 14 KIF2C kinesin family member 2C

TPPP tubulin polymerization promoting protein

CLASP 1 cytoplasmic linker associated protein 1

Neutrophil Activation via Adherence on Endothelial Cells

ITPR1 inositol 1,4,5-trisphosphate receptor type

1

MME membrane metallo-endopeptidase

MMP9 matrix metallopeptidase 9

NCF4 neutrophil cytosolic factor 4

NCF2 neutrophil cytosolic factor 2

NFKBIA NFKB inhibitor alpha

PDPK1 3-phosphoinositide dependent protein kinase 1

PLCG1 phospholipase C gamma 1

PRKCA protein kinase C alpha

PRKCB protein kinase C beta

PRKCZ protein kinase C zeta

PRKCD protein kinase C delta

MAPK3 mitogen-activated protein kinase 3

MAPK1 mitogen-activated protein kinase 1

MAP2K1 mitogen-activated protein kinase kinase 1

MAP2K2 mitogen-activated protein kinase kinase 2

PTK2 protein tyrosine kinase 2

PXN paxillin

RAC1 ras-related C3 botulinum toxin substrate 1

(rho family, small GTP binding protein Racl)

RAF1 Raf-1 proto-oncogene, serine/threonine kinase

SELE selectin E

SELL selectin L

SELPLG selectin P ligand

SELP selectin P

SYK spleen tyrosine kinase TLN1 talin 1

TNS1 tensin 1

VCAM1 vascular cell adhesion molecule 1

VCL vinculin

VAV1 vav guanine nucleotide exchange factor 1

MADCAM1 mucosal vascular addressin cell adhesion molecule 1

IQGAP1 IQ motif containing GTPase activating protein 1

BCARl BCARl, Cas family scaffolding protein

WASF2 WAS protein family member 2

BAIAP2 BAI1 associated protein 2

PLCB1 phospholipase C beta 1

NCF1 neutrophil cytosolic factor 1

Plasmin Effects in Inflammation

ENOl enolase 1

F2R coagulation factor II thrombin receptor

F12 coagulation factor XII

FN1 fibronectin 1

FOS FBJ murine osteosarcoma viral

oncogene homolog

GNA15 G protein subunit alpha 15

GNA12 G protein subunit alpha 12

GNAQ G protein subunit alpha q

IL1B interleukin 1 beta

1KB KB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta

ILIA interleukin 1 alpha

JAK1 Janus kinase 1

JUN jun proto-oncogene

KLK1 kallikrein 1

KLKB1 kallikrein Bl

KNG1 kininogen 1

MAP3K1 mitogen-activated protein kinase kinase kinase 1

MAP3K11 mitogen-activated protein kinase kinase kinase 11

MMP3 matrix metallopeptidase 3

MMP13 matrix metallopeptidase 13

MMP1 matrix metallopeptidase 1

NFKBIA NFKB inhibitor alpha

SERPINE1 serpin family E member 1

PDPK1 3-phosphoinositide dependent protein kinase 1 PLAT plasminogen activator, tissue type

PLAU plasminogen activator, urokinase

PLAUR plasminogen activator, urokinase

receptor

PLG plasminogen

SERPINF2 serpin family F member 2

PRKCE protein kinase C epsilon

MAPK3 mitogen-activated protein kinase 3

MAPK1 mitogen-activated protein kinase 1

MAP2K3 mitogen-activated protein kinase kinase

3

MAP2K1 mitogen-activated protein kinase kinase

1

MAP2K7 mitogen-activated protein kinase kinase

7

MAP2K6 mitogen-activated protein kinase kinase

6

MAP2K2 mitogen-activated protein kinase kinase

2

PXN paxillin

RAC1 ras-related C3 botulinum toxin substrate

1 (rho family, small GTP binding protein Racl)

RAF1 Raf-1 proto-oncogene, serine/threonine kinase

RASGRF1 Ras protein specific guanine nucleotide releasing factor 1

S100A10 SI 00 calcium binding protein A10

CCL2 C-C motif chemokine ligand 2

CCL20 C-C motif chemokine ligand 20 MAP2K4 mitogen-activated protein kinase kinase

4

SRC SRC proto-oncogene, non-receptor tyrosine kinase

STAT1 signal transducer and activator of

transcription 1

STAT3 signal transducer and activator of

transcription 3

TF transferrin

TGFB1 transforming growth factor beta 1

TNF tumor necrosis factor

TYK2 tyrosine kinase 2

TFPI2 tissue factor pathway inhibitor 2

BCARl BCARl, Cas family scaffolding protein

RASGRP1 RAS guanyl releasing protein 1

GNA13 G protein subunit alpha 13

SPINK5 serine peptidase inhibitor, Kazal type 5

PLGRKT plasminogen receptor with a C-terminal lysine

Platelet Activation via Adhesion Molecules

F3 coagulation factor III, tissue factor

PTK2B protein tyrosine kinase 2 beta

CERTG Fc fragment of IgE receptor Ig

FYN FYN proto-oncogene, Src family tyrosine kinase

GP1BB glycoprotein lb platelet beta subunit

GP5 glycoprotein V platelet

GP1BA glycoprotein lb platelet alpha subunit

GP9 glycoprotein IX platelet

GRB2 growth factor receptor bound protein 2

ARHGAP35 Rho GTPase activating protein 35

CXCL8 C-X-C motif chemokine ligand 8

IL6 interleukin 6

ITGA6 integrin subunit alpha 6

ITGA2 integrin subunit alpha 2

ITGA2B integrin subunit alpha 2b

ITGB1 integrin subunit beta 1

ITGB3 integrin subunit beta 3

ITPR1 inositol 1,4,5-trisphosphate receptor type 1

LCP2 lymphocyte cytosolic protein 2

LYN LYN proto-oncogene, Src family tyrosine kinase

MAP3K1 mitogen-activated protein kinase kinase kinase 1

MYLK myosin light chain kinase

NOS3 nitric oxide synthase 3

PDPK1 3-phosphoinositide dependent protein kinase 1 PLCG1 phospholipase C gamma 1

PLCG2 phospholipase C gamma 2

RKCA protein kinase C alpha

MAPK3 mitogen-activated protein kinase 3

MAPK1 mitogen-activated protein kinase 1

PRKG1 protein kinase, cGMP-dependent, type I

MAP2K1 mitogen-activated protein kinase kinase 1

MAP2K6 mitogen-activated protein kinase kinase 6

MAP2K2 mitogen-activated protein kinase kinase 2

PTK2 protein tyrosine kinase 2

PTPRJ protein tyrosine phosphatase, receptor type

J

PXN paxillin

RAC1 ras-related C3 botulinum toxin substrate 1

(rho family, small GTP binding protein Racl)

RAF1 Raf-1 proto-oncogene, serine/threonine kinase

RAP1A, member of RAS oncogene family

ROCK1 Rho associated coiled-coil containing protein kinase 1

SOS1 SOS Ras/Rac guanine nucleotide exchange factor 1

SRC SRC proto-oncogene, non-receptor tyrosine kinase

STX4 syntaxin 4

SYK spleen tyrosine kinase

TLN1 talin 1

tumor necrosis factor TNS1 tensin 1

VCL vinculin

VAV1 vav guanine nucleotide exchange factor 1

__ Wiskott-Aldrich syndrome

VWF von Willebrand factor

VAMP8 vesicle associated membrane protein 8

SNAP23 synaptosome associated protein 23kDa

IQGAP1 IQ motif containing GTPase activating protein 1

BCARl BCARl, Cas family scaffolding protein

PIP5K1C phosphatidylinositol-4-phosphate 5-kinase type 1 gamma

LAT linker for activation of T-cells

GP6 glycoprotein VI platelet

APBB1IP amyloid beta precursor protein binding family B member 1 interacting protein

Platelet Activation via GPCR Signaling

GNAS GNAS complex locus

GNAQ G protein subunit alpha q

t HTR2A 5-hydroxytryptamine receptor 2A

ITGA2 integrin subunit alpha 2

ITGB1 integrin subunit beta 1

ITGB3 integrin subunit beta 3

ITPR1 inositol 1,4,5-trisphosphate receptor type 1

MPL MPL proto-oncogene, thrombopoietin

receptor

MYLK myosin light chain kinase

NOS3 nitric oxide synthase 3

P2RY1 purinergic receptor P2Y1

PDPK1 3-phosphoinositide dependent protein

kinase 1

I PRKCA protein kinase C alpha

MAPK3 mitogen-activated protein kinase 3

MAPK1 mitogen-activated protein kinase 1

PRKG1 protein kinase, cGMP-dependent, type I

MAP2K1 mitogen-activated protein kinase kinase 1

MAP2K2 mitogen-activated protein kinase kinase 2

PTAFR platelet activating factor receptor

PTGER4 prostaglandin E receptor 4

PTGIR prostaglandin 12 (prostacyclin) receptor (IP)

PTGFR prostaglandin F receptor

RAC1 ras-related C3 botulinum toxin substrate 1

(rho family, small GTP binding protein Racl) RAF1 Raf-1 proto-oncogene, serine/threonine kinase

RAPIA RAPIA, member of RAS oncogene family

RASGRF1 Ras protein specific guanine nucleotide releasing factor 1

ROCK1 Rho associated coiled-coil containing protein kinase 1

STX4 syntaxin 4

TBXA2R thromboxane A2 receptor

THPO thrombopoietin

TLN1 talin 1

WAS Wiskott-Aldrich syndrome

VAMP8 vesicle associated membrane protein 8

SNAP23 synaptosome associated protein 23kDa

IQGAP1 IQ motif containing GTPase activating protein 1

F2RL3 F2R like thrombin/trypsin receptor 3

RASGRP1 RAS guanyl releasing protein 1

GNA13 G protein subunit alpha 13

PLCB1 phospholipase C beta 1

APBB1IP amyloid beta precursor protein binding family B member 1 interacting protein

P2RY12 purinergic receptor P2Y12

Positive Acute Phase Proteins Synthesis

Name Description

A2M alpha-2-macroglobulin

SERPINA3 serpin family A member 3

C3 complement component 3 CEBPB CCAAT/enhancer binding protein beta

CEBPD CCAAT/enhancer binding protein delta

CP ceruloplasmin (ferroxidase)

CRP C-reactive protein, pentraxin-related

EGR1 early growth response 1

F8 coagulation factor VIII

FN1 fibronectin 1

GHR growth hormone receptor

GH1 growth hormone 1

GRB2 growth factor receptor bound protein 2

HIF1A hypoxia inducible factor 1 alpha subunit

HNF4A hepatocyte nuclear factor 4 alpha

HP haptoglobin

HPX hemopexin

IL1B interleukin 1 beta

IL1RAP interleukin 1 receptor accessory protein

ILIA interleukin 1 alpha

IL1R1 interleukin 1 receptor type 1

IL6ST interleukin 6 signal transducer

IL6R interleukin 6 receptor

IL6 interleukin 6

IRAKI interleukin 1 receptor associated kinase 1

JAK1 Janus kinase 1

JAK2 Janus kinase 2

LBP lipopolysaccharide binding protein

MBL2 mannose binding lectin 2

MYD88 myeloid differentiation primary response 88

NFKBIA NFKB inhibitor alpha

ORM1 orosomucoid 1

SERPINE2 serpin family E member 2

SERPINA1 serpin family A member 1 PPARA peroxisome proliferator activated receptor alpha

MAPK8 mitogen-activated protein kinase 8

MAPK1 mitogen-activated protein kinase 1

MAP2K1 mitogen-activated protein kinase kinase 1

MAP2K2 mitogen-activated protein kinase kinase 2

PTPN11 protein tyrosine phosphatase, non-receptor type 11

RA 1 1 Raf-1 proto-oncogene, serine/threonine kinase

SAA1 serum amyloid Al

MAP2K4 mitogen-activated protein kinase kinase 4

SOS1 SOS Ras/Rac guanine nucleotide exchange factor 1

SRF serum response factor

STAT3 signal transducer and activator of

transcription 3

STAT5A signal transducer and activator of

transcription 5A

MAP3K7 mitogen-activated protein kinase kinase kinase 7

TLR4 toll like receptor 4

TNF tumor necrosis factor

TNFRSF1B tumor necrosis factor receptor superfamily member IB

TNFRSF1A tumor necrosis factor receptor superfamily member 1A

TRAF6 TNF receptor associated factor 6

TRAF2 TNF receptor associated factor 2

TYK2 tyrosine kinase 2

VWF von Willebrand factor

TRADD TNFRSF1A associated via death domain

MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2

IRAK4 interleukin 1 receptor associated kinase 4 Protein Folding

SCARB1 scavenger receptor class B member 1

MAPK14 mitogen-activated protein kinase 14

FYN FYN proto-oncogene, Src family tyrosine kinase

GP1BB glycoprotein lb platelet beta subunit

GP1BA glycoprotein lb platelet alpha subunit

ITPR1 inositol 1,4,5-trisphosphate receptor type 1

LCP2 lymphocyte cytosolic protein 2

LY LYN proto-oncogene, Src family tyrosine kinase

MATK megakaryocyte-associated tyrosine kinase

MAP3K1 mitogen-activated protein kinase kinase kinase 1

PLCG2 phospholipase C gamma 2

PRKCA protein kinase C alpha

MAPK8 mitogen-activated protein kinase 8

MAP2K6 mitogen-activated protein kinase kinase 6

ROCK1 Rho associated coiled-coil containing protein kinase 1

MAP2K4 mitogen-activated protein kinase kinase 4

SYK spleen tyrosine kinase

VAV1 vav guanine nucleotide exchange factor 1

YES1 YES proto-oncogene 1, Src family tyrosine kinase

LAT linker for activation of T-cells Scavenger Receptors in Platelet Aggregation

TAM Receptors in Platelet Aggregation

Name Description

AKT1 v-akt murine thymoma viral oncogene homolog 1

AXL AXL receptor tyrosine kinase GAS6 growth arrest specific 6

PDPK1 3-phosphoinositide dependent protein kinase 1

PROS1 protein S (alpha)

TYR03 TYR03 protein tyrosine kinase

VWF von Willebrand factor

MERTK MER proto-oncogene, tyrosine kinase

Vascular Endothelial Cell Activation by Blood Coagulation Factors

CXCL8 C-X-C motif chemokine ligand 8

IL6 interleukin 6

IRAKI interleukin 1 receptor associated kinase 1

ITPR1 inositol 1,4,5-trisphosphate receptor type 1

JAK2 Janus kinase 2

JUN jun proto-oncogene

K Gl kininogen 1

MYD88 myeloid differentiation primary response

88

NFKBIA NFKB inhibitor alpha

YBX1 Y-box binding protein 1

PDPK1 3-phosphoinositide dependent protein kinase 1

PLCB3 phospholipase C beta 3

PRKCA protein kinase C alpha

MAPK3 mitogen-activated protein kinase 3

MAPK1 mitogen-activated protein kinase 1

MAP2K1 mitogen-activated protein kinase kinase 1

MAP2K2 mitogen-activated protein kinase kinase 2

PROC protein C, inactivator of coagulation

factors Va and Villa

PROS1 protein S (alpha)

RAF1 Raf-1 proto-oncogene, serine/threonine kinase

RASGRF1 Ras protein specific guanine nucleotide releasing factor 1

CCL2 C-C motif chemokine ligand 2

SRC SRC proto-oncogene, non-receptor

tyrosine kinase

STAT1 signal transducer and activator of

transcription 1

STAT3 signal transducer and activator of

transcription 3

TFPI tissue factor pathway inhibitor

TLR4 toll like receptor 4

TNF tumor necrosis factor TRAF6 TNF receptor associated factor 6

TYK2 tyrosine kinase 2

VCAM1 vascular cell adhesion molecule 1

VEGFA vascular endothelial growth factor A

F2RL3 F2R like thrombin/trypsin receptor 3

RASGRP1 RAS guanyl releasing protein 1

PROCR protein C receptor

PLCB1 phospholipase C beta 1

IRAK4 interleukin 1 receptor associated kinase 4

OCLN occludin